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Abstract
Physical and psychological stressors trigger activation of the hypothalamo-pituitary-adrenocortical
(HPA) axis that leads to enhanced secretion of glucocorticoids e.g. cortisol. Moreover, chronic activa-
tion of this pathway may elevate oxidative stress that is linked to the onset of insulin resistance and
cardiovascular diseases (CVD). Our laboratory previously found that oxidative stress increases ﬂux
through metabolic circuits such as the hexosamine biosynthetic pathway (HBP), in eﬀect increasing its
modiﬁcation of target proteins post-transcriptionally with O-GlcNAc moeities. This in turn may alter
protein function and contribute to the onset of myocardial insulin resistance and impaired contractile
function. Since the underlying mechanisms linking chronic stress to cardiometabolic pathophysiology
are poorly understood, we hypothesised that cortisol elicits myocardial oxidative stress, HBP activa-
tion, and decreased glucose uptake (due to attenuated glucose transport functionality) with detrimental
outcomes, i.e. insulin resistance and apoptosis.
To investigate this hypothesis we established an in vitro model using HL-1 cardiomyocytes, with which
we evaluated the degree of O-GlcNAcylation and oxidative stress in response to a range of time-dose
treatments with dexamethasone (synthetic glucocorticoid). Glucose transporter 4 (GLUT4) transloca-
tion to the sarcolemma was also assessed. In agreement with the literature, results suggest that GLUT4
translocation is signiﬁcantly decreased subsequent to dexamethasone treatment. Although no signiﬁ-
cant diﬀerences were observed with regards to oxidative stress or O-GlcNAcylation, the data show that
dexamethasone increased the latter with a maximal eﬀect after two hours exposure to the 10−6 M dose.
Although our results were not conclusive, the data suggest a potential novel link between dexametha-
sone exposure, HBP activation and decreased GLUT4 translocation. Based on our ﬁndings we propose
that detrimental eﬀects of chronic stress on the heart may be mediated by increased HBP ﬂux. Given
that glucocorticoid excess and GLUT4 dysregulation have been associated with insulin resistance (and
related metabolic derangements and diseases), these results provide new targets for potential thera-
peutic agents.
ii
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Uittreksel
Fisiese sowel as psigologiese stressors veroorsaak die aktivering van die hipotalamiese-hipoﬁseale-bynier
(HHB) pad wat lei tot die verhoogde sekresie van glukokortikoïede soos kortisol. Kroniese aktivering van
hierdie pad kan ook oksidatiewe stres verhoog wat weer tot insulienweerstandigheid en kardiovaskulêre
siektes (KVS) kan lei. Navorsing uit ons laboratorium het voorheen bewys dat oksidatiewe stres 'n toe-
name in vloei deur metaboliese paaie soos die heksoamine biosintetiese pad (HBP) kan veroorsaak deur
die modiﬁsering van teikenproteïene met O-GlcNAc motiewe. Dit kan weer proteïen funksie verander
en bydra tot die ontstaan van miokardiale insulienweerstandigheid en verswakte kontraktiele funksie.
Die onderliggende meganismes wat kroniese stres aan kardiometaboliese patoﬁsiologie verbind word
nog nie goed verstaan nie, daarom is ons hipotese dat kortisol miokardiale oksidatiewe stres veroor-
saak, die HBP pad aktiveer, en glukose opname verminder (deur die funksionele onderdrukking van
glukose transport), wat nadelige uitkomste soos insulienweerstandigheid en apoptose tot gevolg kan hê.
Om hierdie hipotese te ondersoek, is 'n in vitro model van HL-1 kardiomiosiete gebruik waarmee
die graad van O-GlcNAsilering en oksidatiewe stres in reaksie op 'n reeks tyd-konsentrasie behan-
delings met deksametasoon (sintetiese glukokortikoïed), bepaal is. Glukose transporter 4 (GLUT4)
translokasie na die sarkolemma is ook geasseseer. In ooreenstemming met die literatuur, is GLUT4
translokasie insiggewend onderdruk tydens deksometasoon behandeling. Alhoewel geen insiggewende
verskille rakende oksidatiewe stres en O-GlcNAsilering gevind is nie, het ons data aangedui dat laasge-
noemde deur deksametasoon vermeerder het na twee ure van blootstelling aan die 10−6 M konsentrasie.
Alhoewel ons resultate geen afdoende bewys lewer nie, stel dit wel voor dat daar 'n potensiële verbin-
tenis tussen deksametasoon behandeling en 'n afname in GLUT4 translokasie is. Gebasseer op ons
bevindings, stel ons voor dat die nadelige eﬀekte van kroniese stres op die hart bemiddel kan word
deur 'n toename in vloei deur die HBP. Gegewe dat 'n oormaat glukokortikoïede en GLUT4 wanreg-
ulering geassosieer is met insulien weerstandigheid (en verbandhoudende metaboliese veranderinge en
siektes), verskaf hierdie resultate nuwe teikens vir potensiële terapeutiese ingrepe.
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FABP Fatty acid binding protein
FACS Fatty acyl CoA synthase
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FADH2 Flavin adenine dinucloetide (reduced)
FAT Fatty acid translocase
FFA Free fatty acid
FITC Fluorescein isothiocyanate
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
G/F Gelatin/Fibronectin
GFAT Glutamine:fructose-6-phosphate amidotransferase
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GLUT Glucose transporter
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GSSG Glutathione (oxidised)
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JNK c-Jun NH2-terminal kinase
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LDH Lactate dehydrogenase
LDL Low density lipoproteins
MAPK Mitogen-activated protein kinase
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MPO Myeloperoxidase
MR Mineralocorticoid receptor
mRNA Messenger ribonucleic acid
NHLBI National Heart, Lung, and Blood Institute
NAD+ Nicotinamide adenine dinucleotide (oxidised)
NADH Nicotinamide adenine dinucleotide (reduced)
NADP+ Nicotinamide adenine dinucleotide phosphatase (oxidised)
NADPH Nicotinamide adenine dinucleotide phosphatase (reduced)
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PE-TxRed R-phycoerythrin-conjugated Texas Red
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PGI Phosphoglycerate isomerase
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PKB Protein kinase B, also known as Akt
PKC Protein kinase C
PMSF Phenylmethanesulfonyl ﬂuoride
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RAGE AGE receptor
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ROS Reactive oxygen species
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Chapter 1
Introduction
The world is getting fat. The McKinsey Quarterly of October 2010 [1], and a plethora of
frightening statistics robustly support this notion. Moreover, according to the World Health
Organisation (WHO) [2], obesity has more than doubled globally since 1980. The International
Diabetes Federation (IDF) estimates that 366 million people have diabetes in 2011 and that
it will escalate to 552 million people by 2030 [3], with type 2 diabetes mellitus (T2DM) ac-
counting for more than 85% - 95% of the total prevalence [4]. To underline the severity of the
current situation, earlier this year the United Nations (UN) at their sixty-sixth general assem-
bly, included diabetes and heart diseases (frequently associated with overweight and obesity)
as socio-economic and development challenges of `epidemic proportions' [5].
Africa has not remained unscathed by this metabolic `epidemic'. The IDF projects a doubling in
the number of people with diabetes in Africa between 2011 and 2030, i.e. from 14.7 to 28 million
[6]. Ziraba et al. [7] compiled research from a number of studies throughout the continent, span-
ning at least a decade, and found that the prevalence of urban overweight/obesity was on the
rise (∼ 35%). The increase was highest among the poor (+50%) and non-educated groups,
although the auent sections of the population (+7%) were also aﬀected. This is a paradoxical
ﬁnding, considering that many people in developing countries remain signiﬁcantly malnourished
[1]. Interestingly, developing countries undergoing socioeconomic and demographic transition
often display a nutrition paradox in which so-called `dual-burden households' have both under-
weight and overweight family members [8]. Furthermore, where T2DM, a disease with many
complications, was once considered to be a disease of wealthy nations, it is now a global aic-
tion [9], with 80% of aﬀected individuals living in low- and middle-income countries [3].
1
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So-called 'Western' eating and lifestyle habits are trending globally e.g. sedentary lifestyles
married to energy rich diets - much too high in processed carbohydrates and lipids - are becom-
ing the norm. This results in an energy imbalance in the body, and consequently leads to an
excess of fuel substrate supply which may be `toxic' to our cells. In most people, fuel substrate
excess invariably leads to metabolic dysregulation and a host of damaging, intracellular alter-
ations with severe functional consequences. This thesis will focus on some myocardial metabolic
derangements and the mechanisms that underlie their pathophysiology in the context of T2DM.
1.1 The metabolic syndrome
A cluster of risk factors have been identiﬁed as key warning signs for diseases involving metabolic
dysregulation. These risk factors are more frequently observed in concert than in isolation
[10], and constitute what is known as the metabolic syndrome. There is often great overlap
of risk factors among metabolic diseases. Therefore, it is likely that a person suﬀering from
diabetes, obesity or cardiovascular disease (CVD) may also be diagnosed with the metabolic
syndrome. Thus, the metabolic syndrome has become an inclusive concept (an umbrella term)
for metabolic disorders. The ability to identify risk factors in patients provides a valuable tool
to assess individual risk proﬁles and susceptibility to metabolic diseases. It also pinpoints risk
areas which allows for its early detection, and provides an opportunity to promote prevention
of cardiometabolic diseases by appropriate lifestyle changes.
1.1.1 Deﬁnition
The two main causes of the metabolic syndrome, and its rapidly increasing spread across the
world, are high caloric diet and physical inactivity. Since it was ﬁrst described by Reaven in
1988 [11], various deﬁnitions have been formulated for the characterisation of the metabolic
syndrome by organisations such as the IDF, and the WHO. In 2009, a number of associations1
met in an attempt to unify the criteria to be considered for diagnosis of the metabolic syndrome
[12]. The physiological parameters agreed on were released in a joint statement2 [refer Table 1.1].
1International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung,
and Blood Institute (NHLBI); American Heart Association (AHA); World Health Federation; International
Atherosclerosis Society; and International Association for the Study of Obesity.
2Furthermore, the revised National Cholesterol Education Program (NCEP) deﬁnition (2004) also includes
patients being treated for dyslipidaemia, hyperglycaemia, or systemic hypertension.
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Risk factors Parameters
Elevated waist circumference Population- and country-speciﬁc
Elevated serum triglycerides ≤ 1.7 mmol/l
Reduced high-density lipoprotein (HDL) cholesterol < 1 mmol/l (males)
< 1.3 mmol/l (females)
Elevated blood pressure ≥ 130 mm Hg (systolic) and/or
≥ 85 mm Hg (diastolic)
Elevated fasting glucose ≥ 5.6 mmol/l
Table 1.1: Criteria for diagnosis of the metabolic syndrome. Diagnosis of the metabolic syndrome
requires detection of three (or more) risk factors within an individual.
Elevated waist circumference, elevated serum triglycerides, reduced high-density lipoprotein
(HDL) cholesterol, elevated blood pressure, and elevated fasting glucose are major indicators of
the manifestation of the metabolic syndrome. The parameter values provided in Table 1.1 (right
column) indicate values that extend beyond the normal range. Detection of three (or more)
of the aforementioned risk factors within an individual constitutes diagnosis of the metabolic
syndrome. However, discussions between the American Heart Association (AHA) and National
Heart, Lung, and Blood Institute (NHLBI), and the IDF recently concluded in the agreement
that visceral adiposity should not be the main prerequisite for diagnosis [12]. Moreover, ele-
vated waist circumference now has population- and country-speciﬁc parameters [refer Table 1.2].
Population Organisation Men Women
European IDF ≥ 94 cm ≥ 80 cm
Caucasian WHO ≥ 94 cm or 102 cm ≥ 80 cm or 88 cm
United States AHA/ATPIII ≥ 102 cm ≥ 88 cm
Asian IDF/WHO ≥ 90 cm ≥ 80 cm
China Cooperative task force ≥ 85 cm ≥ 80 cm
Sub-Saharan Africa IDF ≥ 94 cm ≥ 80 cm
Ethnic Central & IDF ≥ 90 cm ≥ 80 cm
South American
Table 1.2: Population- and country-speciﬁc thresholds of waist circumference.
AHA/NHLBI guidelines for metabolic syndrome recognise that risk for CVD and diabetes is
increased beyond waist circumference measurements of 94 cm in men, and 80 cm in women,
and suggest that individuals or populations with increased insulin resistance consider these as
optional cut-oﬀ points.
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The risk factors of the syndrome are varied but all point to metabolic dysregulation. Therefore,
it is understandable that the metabolic syndrome results in an alteration of glucose homeostasis
and glucose intolerance, which is an indicator of insulin insensitivity3 [13]. To compensate, an
increase in insulin blood levels can occur, but since sensitivity to insulin has decreased, glucose
levels in the blood stream are often increased and may give rise to a diabetic state [13].
1.1.2 Aetiology
Aside from lack of physical activity and a high caloric diet, there is evidence to indicate that
psychosocial, neuroendocrine, immunogenic, and oxidative stress are key factors in the devel-
opment of metabolic syndrome, CVD, and T2DM [14]. Identifying causes (whether systemic
or environmental) provides clues to pinpointing molecular mechanisms underlying the patho-
physiology of the syndrome. The mechanisms are not yet fully understood, however, a number
of theories have been proposed, frequently based on insulin resistance [15]. [Insulin resistance
and its possible underlying mechanisms are discussed in Section 1.4].
1.2 Cardiovascular complications
The metabolic syndrome, which has also been referred to as `Reaven's Syndrome X' [15], has
become a major health concern as a result of its strong link to T2DM and CVD [16]. CVD has
been described as the major cause of morbidity and mortality associated with diabetes [17].
According to Mottillo et al. [16] metabolic syndrome is associated with a 2-fold increase in
risk for CVD, CVD mortality, myocardial infarction, and stroke; and a 1.5-fold increase in risk
for all-cause mortality. The metabolic syndrome is further associated with the development of
atherosclerosis [10] and heart failure [18]. Moreover, independent factors such as ageing and
genetic susceptibility may accelerate and/or exaggerate disease risks or complications, and the
mechanisms that mediate the tissue-damaging eﬀects, which are yet to be discussed [19].
Other complications that may arise due to the metabolic syndrome or some of the associated
risk factors include triglyceride accumulation. Moreover, it may also arise due to hyperlip-
idaemia, or obesity, and when it occurs within cardiomyocytes, may be associated with cell
death (as a result of toxic lipid intermediates), and impaired contractile function [20]. It is
3Insulin insensitivity can be considered as the reduced capacity of insulin to promote glucose uptake in cells.
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 1. INTRODUCTION 5
also relatively common in non-ischaemic heart failure, e.g. failing hearts display attenuated
fatty acid (FA) oxidation, and if myocardial insulin resistance is present concomitantly, glucose
oxidation may be impaired too, resulting in `energy starvation' of the heart [20].
1.3 Metabolic substrates of the heart
For nearly a century, it has been known that there is competition between substrates for mito-
chondrial respiration in animal tissues. The most important interaction, quantitatively, lies in
the glucose fatty acid cycle [refer Section 1.3.4.1], also known as the Randle cycle - described
in 1963 by Randle et al. [21] as a reciprocal metabolic relationship, rather than a dependent
one [22].
The heart, like the body, is an omnivore in terms of its fuel substrate selection, i.e. FAs,
glucose, lactate, and ketone bodies. However, under normal physiologic conditions the heart
utilises FAs as its primary energy substrate4 and since cardiomyocytes have limited capacity
for triglyceride storage, the uptake and oxidation of FAs is tightly regulated [24]. On this
metabolic tightrope, the heart can adapt to the prevailing milieu, and convert the chemical
energy contained in myriad oxidisable substrates to meet the energy demands of contraction
[25].
Substrate metabolism is kept in a delicate balance. Substrate uptake, CO2 production and
O2 consumption are matched, almost precisely, with ATP turnover [25]. At the same time, pro-
vision of free FAs promote oxidation and storage of FAs, it inhibits glucose oxidation (Randle
cycle), and if glycogen reserves are low, glucose storage may be promoted. On the other hand,
availability of glucose promotes glucose oxidation, storage of both glucose and lipids, and in-
hibits FA oxidation (reverse Randle cycle) [22].
1.3.1 Glucose metabolism
Before glucose metabolism can take place, glucose needs to enter the cell, and for this to happen
eﬃciently, glucose transporters need to be stimulated to migrate to the cell membrane. Insulin
stimulation and the insulin signaling pathway are a vital part of the process. When insulin
binds to the extracellular insulin receptor a phosphorylation cascade is triggered. This sig-
nalling pathway functions to mediate glucose transporter 4 (GLUT4) translocation to the cell
4FAs contribute approximately 70% of the ATP required for normal heart function [23].
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membrane so that glucose transport into the cell can be facilitated.
Under normal circumstances, insulin binds to the α subunit of the insulin receptor (IR) and
activates the tyrosine kinase in the β subunit within the cell. The activated tyrosine kinase phos-
phorylates the insulin receptor substrate (IRS) proteins.5 Then, the phosphotyrosine residues
on IRS become targets for regulation by the p85 subunit of phosphoinositide 3-kinase (PI3K)
which in turn catalyzes phosphatidylinositol 4,5 diphosphate into phosphatidylinositol 3,4,5
triphosphate. Downstream, phosphatidylinositol-dependent kinase and Akt (a serine/threonine
kinase also known as protein kinase B, PKB) have a pleckstrin homology domain that facili-
tate the migration of GLUT4 to the membrane [26]. This PI3K-Akt6 activation is crucial for
insulin-stimulated GLUT4 translocation to the sarcolemma [illustrated in steps 1 - 4 of Figure
1.1], and thus for allowing glucose into the cell.
Once in the cell, glucose becomes phosphorylated to glucose-6-phosphate and can either be
stored as glycogen or proceed through the glycolytic pathway to form pyruvate. Pyruvate de-
hydrogenase irreversibly catalyses the decarboxylation of pyruvate into acetyl CoA. Acetyl CoA
enters mitochondria to undergo glycolytic oxidation via the citric acid cycle, producing CO2
and H2O.
1.3.1.1 Glucose transporters in metabolism
GLUT1 and GLUT4 are the two major glucose transporter isoforms responsible for basal and
insulin-stimulated glucose uptake. These have been identiﬁed in rodent cardiomyocytes and
speciﬁcally, in HL-1 mouse cardiomyocytes [28]. The two primary sites of insulin-dependent
glucose disposal, and GLUT4 synthesis, are muscle and adipose tissue. In isolated rat cardio-
myocytes GLUT1 accounts for approximately 30% of total glucose carriers (as opposed to ∼ 5 -
10% in adipocytes and skeletal muscle), and GLUT4 for about 70% [29]. As the name implies,
GLUT4 proceeds to transport glucose, increasing its ﬂux into the cell by a net 10- to 40-fold
[27]. Upon extracellular insulin stimulation, GLUT4 is redistributed from intracellular storage
vesicles to the cell membrane. GLUT4 is present in two vesicle populations in cardiomyocytes:
pool 1 contains GLUT4 and little or no GLUT1; whilst pool 2, aside from GLUT4, contains
5When insulin signalling becomes dysregulated, serine (instead of tyrosine) on the IRS is phosphorylated.
IRS-1 has more than 70 potential serine phosphorylation sites, and their phosphorylation generally aﬀect IRS
signalling negatively [26].
6Substantial evidence exists in support of Akt being involved in insulin-stimulated GLUT4 translocation to
the cell membrane, promoting glucose transport. PI3K is an intermediate in this insulin signalling pathway but
Akt is the furthest-known downstream target [27].
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a substantial GLUT1 and secretory carrier membrane proteins (SCAMPs) component [29].
Becker et al. [30] elaborate on hypothetical models of distribution and traﬃcking of glucose
transporters. The models diﬀer with regard to component composition of the intracellular
pools, and the diﬀerential eﬀects of insulin stimulation on them.
Interestingly, contraction also stimulates GLUT4 translocation but by a diﬀerent mechanism,
independent of insulin stimulation [31]. This is observed in skeletal muscle, but is more preva-
lent in cardiac muscle where contraction occurs continuously. GLUT4 translocation may also
be stimulated by AMP-activated protein kinase (AMPK), an enzyme (activated by exercise)
involved in cellular energy homeostasis. AMPK inhibits anabolic and promotes catabolic
processes by inﬂuencing various mechanisms (including increased delivery and metabolism of
both glucose and fatty acids) [32].
1.3.2 Metabolic dysregulation due to excess glucose
When a surplus glucose is present in the cell, and it cannot be stored as glycogen, glucose
metabolism produces an overabundance of acetyl CoA (a precursor to the lipogenic pathway)
in mitochondria. Excess unoxidised acetyl CoA is shuttled out of mitochondria back to the
cytosol where it is carboxylated by acetyl CoA carboxylase (ACC) to malonyl CoA - the pri-
mary intermediate of FA synthesis. In this way, insulin can also stimulate lipogenesis. Malonyl
CoA in abundance inhibits carnitine palmitoyl transferase-1 (CPT-1), the rate-limiting enzyme
which facilitates movement of FAs into the mitochondrion. In other words, increased malonyl
CoA exerts an inhibitory eﬀect on FA oxidation, and this is referred to as the McGarry eﬀect
[33], [34]. Within the pre- or full-blown diabetic milieu (high FA supply), blunted FA oxida-
tion leads to an accumulation of FA CoA and/or its derivatives, triglycerides and/or ceramide,
which interferes with the phosphorylation of Akt.7
Unger [34] implicates increased insulin-stimulated lipogenesis as a cause of glucometabolic
insulin resistance [see Figure 1.1], and then continues to explain how this form of insulin resis-
tance may protect against severe lipotoxicity [Figure 1.2]. Here it is important to note the
role of the glucose transporter, GLUT4. By limiting the entry of glucose into the cell, malonyl
CoA production is reduced with two beneﬁcial eﬀects. Firstly, it lowers FA acid synthesis;
and secondly, it removes the inhibition of CPT-1, thereby allowing FA oxidation to proceed.
7Notably, the presence of the sphingomyelin derivative ceramide has been shown to induce a 60% reduction
in insulin-stimulated Akt activity (and thus attenuated GLUT4 translocation and glucose uptake) [27].
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Figure 1.1: Increased insulin-stimulated lipogenesis contributes to the development of glucometabolic
insulin resistance (adapted from Unger [34]). Insulin action is initiated when it binds to its receptor
(1). A tyrosine phosphorylation cascade results in which insulin receptor substrate (IRS-1)-associated
phosphoinositide 3-kinase (PI3K) activity (2) and the phosphorylation of Akt (3) are essential for
GLUT4 translocation (4) from glucose transporter storage vesicles (GSVs) in the cytoplasm to the
sarcolemma. Once at the membrane, it transports glucose into the cell. Excess glucose that cannot be
metabolised oxidatively or stored as glycogen enters the lipogenic pathway as acetyl CoA (5). Acetyl
CoA carboxylase (ACC) catalyses the formation of malonyl CoA, the ﬁrst step in the synthesis of long-
chain fatty acids (FA CoA) (6), triacylglycerols (TGs) and their lipotoxic derivatives e.g. ceramides
(not shown). Increased malonyl CoA inhibits carnitine palmitoyl transferase 1 (CPT-1), an enzyme
which mediates the transport of long-chain fatty acids (FAs) into the mitochondrial matrix. CPT-1
inhibition blocks FA oxidation (McGarry eﬀect). As a result, intracellular Fa CoA and/or derivatives
thereof accumulate, which interferes with the phosphorylation of Akt (3).
Collectively these eﬀects limit accumulation of intracellular lipids, ultimately reversing their
inhibitory eﬀect on GLUT4 translocation. This theory makes sense from a homeostatic per-
spective. However, it also demonstrates how natural defences become detrimental if chronically
activated e.g. chronic hyperglycaemia will defeat the purpose of this mechanism. Under these
conditions intracellular homeostasis will not be achieved, but instead a greater insensitivity to
insulin.
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Figure 1.2: Glucometabolic insulin resistance may protect against severe lipotoxicity. Accumulated
FAs or lipid derivatives such as ceramide (1) blunt GLUT4 translocation and thereby glucose transport
into the cell (2). Malonyl CoA formation is reduced (3), and so too FA-CoA synthesis (4) removing
the CPT-1 inhibition (5). Consequently, FA oxidation by mitochondria increases, producing CO2 and
H2O (6). In this way, the accumulation of intracellular lipids (including ceramide) will be lessened.
Adapted from Unger [34].
1.3.3 Fatty acid metabolism
The greater the availability of free fatty acids (FFAs), the higher its uptake into cells. Myo-
cardial FA uptake occurs via passive diﬀusion or by protein-mediated transport across the
sarcolemma, facilitated by proteins such as fatty acid translocase (FAT) and plasma membrane
fatty acid binding protein (FABP). FFAs, which are usually transported in non-esteriﬁed form,
bind to the FABP where it can immediately be esteriﬁed to fatty acyl CoA by fatty acyl CoA
synthase (FACS). Depending on their composition and the energy demands of the cell, fatty
acyl CoAs, may be shunted into one of three pathways: β-oxidation, glycerolipid formation, or
sphingolipid formation [35]. β-oxidation of acyl CoAs takes place in the mitochondrion8 where
energy equivalents can be donated to the electron transport chain (ETC) for ATP synthesis.
8CPT-1 regulates the entry of long-chain fatty acyl CoAs into mitochondria but short-chain acyl CoAs
can bypass the CPT shuttle system (consisting of CPT-1 and CPT-2 in the outer and inner mitochondrial
membranes, respectively). Thus, it is unlikely that short-chain acyl CoAs contribute to the formation of other
lipid metabolites [35].
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1.3.4 Metabolic dysregulation due to excess fatty acids
FAs, particularly non-esteriﬁed fatty acids, known to play a role in the metabolic syndrome, are
released from adipose tissue into the bloodstream after lipolysis. The release of FAs increases
with greater adipose mass. Consequently, greater release of FAs will continue despite elevated
insulin levels present in (overweight) diabetic individuals [36] which would normally suppress
lipolysis [37]. In the fasting state, FAs are the primary, nutrient energy source, but within the
obese context FA availability exceeds myocardial metabolic demand leading to dysregulation.
Grundy [36] suggests that metabolic fuel excess initiates defence mechanisms, but that such
processes may contribute to increased metabolic risk factors.
1.3.4.1 Glucose Fatty Acid Cycle
The glucose fatty acid cycle [Figure 1.3], also known as the Randle cycle, after Philip Randle [21]
was put forward as a mechanism of FA-induced insulin resistance. It posits that an increase in
FA oxidation results in augmentation of the acetyl CoA/CoA and NADH/NAD+ ratios within
the mitochondrion. Increased acetyl CoA and NADH would inactivate pyruvate dehydrogenase
(PDH). As a result, citrate concentrations would rise, leading to inhibition of phosphofructoki-
nase (PFK). This, in turn, results in accumulation of glucose-6-phosphate causing an inhibition
of hexokinase (HK) activity and decreased glycolytic ﬂux. With glycolysis thus attenuated,
intracellular glucose concentrations increase and glucose uptake diminishes [38].
Various researchers challenged the glucose fatty acid cycle hypothesis [39]. For example, Shul-
man [38] cited two reasons for disagreeing with the Randle hypothesis. Firstly, that decreased
intramuscular glucose-6-phosphate concentrations may be observed under conditions of fat-
induced insulin resistance. Secondly, the interference that FAs seem to exert (in a very early
step) on insulin-stimulated GLUT4 transporter and/or hexokinase activity.
Here, Shulman [38] argues that increasing intracellular FA metabolites (e.g. diacylglycerol,
FA CoAs, or ceramides) trigger a serine/threonine kinase cascade, which leads to phosphoryla-
tion of serine/threonine sites on IRS. Furthermore, Shulman suggests that the phosphorylation
cascade may be initiated by PKCθ, and that phosphorylation of the serine residues (rather
than threonine) lead to impaired PI3K activation. In turn, this results in reduced activation of
glucose transport and other downstream processes.
In summary, the theories discussed make it clear that both glucose and FA excess have pathogenic
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Figure 1.3: Schematic representation of the glucose fatty acid cycle, also known as the Randle cycle.
Randle et al. [21] suggested that greater FA oxidation would increase acetyl CoA and NADH resulting
in the inactivation of PDH. As a result, citrate concentrations would rise, leading to inhibition of PFK,
and thus, accumulation of glucose-6-phosphate. Upstream, HK activity would be inhibited leading to
decreased glycolytic ﬂux. Consequently, intracellular glucose concentrations would increase, thereby
reducing glucose uptake. Figure adapted from Shulman [38].
eﬀects, compounded in unison. Taegtmeyer & Stanley [25] used the term `cardiac lipotoxicity'9
coined by Roger Unger, and extended the concept to include the adverse eﬀects of glucose
and resulting toxic metabolites, and called it `cardiac glucolipotoxicity'. This serves to empha-
sise the point that fuel excess is toxic to (myocardial) cells, and if left unchecked can lead to
metabolic dysregulation. Dysregulation of both glucose and fatty acid metabolism repeatedly
point to insulin resistance.
1.4 Insulin resistance
A number of theories have been proposed to describe the mechanisms of defective insulin sig-
nalling. Some of these mechanisms were discussed in Sections 1.3.2 [Metabolic dysregulation due
to excess glucose] and 1.3.4 [Metabolic dysregulation due to excess fatty acids ] since the onset
of insulin resistance usually coincides with dysregulation of metabolism due to glucose and/or
FA excess.
9Taegtmeyer et al. [25] assert that lipid-lowering interventions or weight loss may rescue the deleterious
sequence of events in which lipotoxicity leads to cell death, contractile dysfunction and heart failure.
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1.4.1 Fatty acid-induced insulin resistance
The most prominent theories surrounding the aetiology of insulin resistance are based on dys-
regulation of fatty acid metabolism. This is probably because excess glucose metabolites (such
as acetyl CoA) also enter the lipogenic pathway contributing to an accumulation of intracellular
FAs.
1.4.1.1 Decreased GLUT4 translocation
In the context of toxic fuel excess, the lipid theory for the development of myocardial insulin
resistance has increasingly been put forward to explain the pathogenesis of the disease. For
example, Sharma et al. [20] emphasise that increased fatty acid delivery (due to obesity and
diabetes), as well as impaired FA oxidation (as in heart failure) can have severe intramyocardial
triglyceride accumulation as a consequence. This accumulation of long chain FAs is a key factor
in the lipid theory.
Unger [34] describes lipid overload and its contribution to the metabolic syndrome, however,
holds that the underlying mechanism leading to the metabolic syndrome is in fact a loss of
leptin10 action, which contrasts the popularly held belief that it is an insulin-resistance syn-
drome.11 Unger [34] also highlights that there is extensive evidence linking glucocorticoids to
obesity [elaborated on in Section 1.5]. It has also been illustrated that high local levels of the
steroid hormone may cause leptin resistance [41]).
1.4.1.2 Decreased expression of insulin receptor
Another FA-induced mechanism postulated to play a role in promoting loss of insulin sensitivity
is the inhibition of insulin receptor (IR) gene expression. It has been shown that palmitate
(FA), inhibits IR expression which results in reduced IR protein in insulin target cells [42].
Furthermore, this reduction in IR expression was found to be due to phosphoinositide-dependent
kinase-1 (PDK-1)-independent phosphorylation of PKC. Phospho-PKC is translocated to the
nucleus, but exactly how it downregulates the IR gene remains unclear. Bhattacharya et al.
[42] also review recent reports that have implicated various PKC isoforms in insulin signalling
10Leptin is a key regulator of energy intake and expenditure. It is a hormone which acts, under normal
physiological conditions, as an appetite suppressant.
11The protective role of leptin and adiponectin against lipotoxicity has gained support from other researchers
as shown in a review by Lewis, Carpentier, Adeli & Giacca [40].
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regulation, and note that expression levels and activity of a few PKC isoforms are also associated
with insulin resistance.
1.4.2 Other contributing factors to insulin resistance
There are also other factors that have been implicated in the pathophysiology of insulin resis-
tance, including glucocorticoids [refer Section 1.5.4], oxidative stress [elaborated on in Section
1.6], and the hexosamine biosynthetic pathway (HBP) [Section 1.7.4]. The HBP is a major
focus of this research project.
1.4.2.1 The hexosamine biosynthetic pathway
The HBP is an overﬂow pathway of glycolysis. Depending on the cell type, two to ﬁve per
cent of glucose that enters cells will ﬂux through the HBP. The pathway, involved primarily in
nutrient sensing, will thus be upregulated by high intracellular glucose levels. Insight into the
HBP shows how glucose shifts to hold a regulatory role in cellular processes. Thus, the role of
glucose is expanded beyond its traditional role(s) in energy metabolism [43].
The HBP is known to be responsible for post-translational glycosylation of target proteins
[44]. This O-linked β-N-acetylglucosamine (O-GlcNAc) intracellular modiﬁcation, occurs on
threonine or serine residues of nucleocytoplasmic proteins. Interestingly, O-GlcNAc and O-
phosphate have been mapped to the same serine or threonine residue on a subset of proteins,
and display extensive crosstalk [45]. It is also known to compete for phosphorylation sites.
O-GlcNAcylation is a highly dynamic process, with rapid cycling in response to cellular signals
[46]. Being responsive to many stimuli and conditions suggests that it holds importance in
many regulatory pathways. O-GlcNAcylation acts as a cellular regulator of growth and prolif-
eration, but mainly holds status as a nutrient- and stress-sensor [47].
Since the focus of this research is on the involvement of stress in the aetiology of insulin
resistance and the metabolic syndrome, the HBP as stress and nutrient sensor is a pertinent
pathway to investigate in the context of metabolic dysregulation. The following section will
review stress and its role in the pathogenesis of the metabolic syndrome.
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1.5 Stress
Stress is another side eﬀect of the modern, westernised lifestyle which takes a bigger toll on
health than realised. Although the stress phenomenon is recognised as a `survival mechanism',
chronic activation of stress responses are known to have adverse eﬀects. Rosmond [10] provides
a historic perspective and quotes the writings of Claude Bernard from 1878: `All the vital
mechanisms, varied as they are, have only one object, that of preserving constant conditions
of life in the internal environment'. About 50 years later the term `homeostasis' was coined by
Walter B. Cannon, who deﬁned it as the `the coordinated physiological process which maintains
most of the steady states in the organisms'. What is most relevant to this study is that Cannon
then (borrowing the terms `stress' and `strain' from physics) proceeded to describe failure to
maintain homeostasis. He explained that a `critical stress' level is one that produces a `breaking
strain', thereby disrupting homeostasis and the ability to maintain it [10]. By 1956, Hans Selye
had expanded the axiom of homeostasis to include the responses mediated by the hypothalamo-
pituitary-adrenocortical (HPA) axis.
1.5.1 Hypothalamo-pituitary-adrenocortical axis
In short, the HPA is a negative-feedback system which involves the hypothalamus and the an-
terior pituitary and its main purpose is to regulate cortisol secretion from the adrenal cortex.
As stresses occur or are perceived, the hypothalamus is stimulated to secrete corticotropin-
releasing hormone (CRH) [refer Figure 1.4]. CRH in turn stimulates adrenocorticotrophic
hormone (ACTH) secretion from the anterior pituitary, which stimulates the adrenal cortex to
secrete cortisol. To complete the feedback loop, cortisol exhibits an inhibitory eﬀect on CRH
and ACTH secretion from the hypothalamus and anterior pituitary, respectively [48].
Figure 1.4: The HPA negative feedback loop in which excess cortisol secretion inhibits the release of
CRH and ACTH from the hypothalamus and anterior pituitary, respectively, thereby limiting further
secretion of cortisol.
A key regulator of the HPA is the hippocampus, which contains both glucocorticoid and
mineralocorticoid receptors, and has a primarily inhibitory eﬀect on basal secretion of cor-
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ticosteroids [49]. Under conditions of elevated glucocorticoid levels, the (rat and primate)
hippocampus may suﬀer damage which becomes exaggerated with increasing age. Therefore, it
is conceivable that protracted stresses may disrupt negative feedback by the persistent down-
regulation of corticosteroid receptors [49]. The receptor loss and neuronal damage caused by
increased corticosteroids further exacerbate the feed-forward cascade. These data indicate that
excessive stress in itself may detrimentally aﬀect regulation of stress responses. The defective
regulation of complex neuroendocrine networks may be a crucial component in development of
metabolic disorders [37].
1.5.2 Glucocorticoids
Glucocorticoids, a class of steroid hormones, are key players in regulating salt and water
metabolism, blood pressure, immune function and metabolism. Glucocorticoids have a myriad
of eﬀects on human behaviour such as sleep patterns, mood and the reception of sensory in-
put, while also playing a substantial role in maintaining brain activities, including prefrontal
cortical cognitive function (speciﬁcally for working memory). Immunologic, cardiovascular,
homeostatic, and metabolic function, are some of the essential physiological functions corti-
sol is involved in which have ensured it the status of most important glucocorticoid [50], [51].
Deemed most important during times of stress, glucocorticoids will provide longer-term signals
capable of overriding acute responses to illness and `reset' metabolism in favour of providing
substrates for oxidative metabolism [15].
Glucocorticoids are produced in the adrenal cortex under control of the HPA, and contribute
to the HPA feedback system. Cortisone is the inactive metabolite in humans that is converted
to the active form, cortisol, in a reversible reaction catalysed by 11β-hydroxysteroid dehydro-
genase (11βHSD) types 1 and 2, respectively. In rodents, corticosterone is the active metabolite.
These steroid hormones diﬀuse readily through cell membranes. There are two types of gluco-
corticoid receptors both of which reside in the cytoplasm in an inactivated state; type I,
mineralocorticoid receptors (MR), and type II, glucocorticoid receptors (GR). Glucocorticoids
bind to, and activate the receptors that then migrate to the nucleus where they exert either
direct or indirect inﬂuences on nuclear transcription. Activated glucocorticoid-receptor com-
plexes can bind directly to DNA and thus enhance or inhibit gene expression of responsive genes
(known as glucocorticoid response elements) by interacting with their promoter regions. Gluco-
corticoids can also aﬀect protein expression indirectly by interacting with transcription factors
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(and not binding directly to DNA). It appears that this indirect mechanism is responsible for
most of the anti-inﬂammatory eﬀects of glucocorticoids [52].
1.5.3 Role of stress in the pathogenesis of the metabolic syndrome
Miller et al. [53] highlight that many theories prominently feature the idea that `chronic stress
fosters disease by activating the HPA axis'. In agreement with this statement, Girod & Brotman
[52] argue that the short-term beneﬁt of the physiologic stress response can be detrimental in the
long term. Rosmond [10] cites Claude Bernard who recognised in 1878, that all living processes
exist in a dynamic state of internal physiologic equilibrium (`milieu intérieur'). Bernard ascribed
this to the organic liquid by which all of the tissue elements are surrounded.
Stress elicits reactions at the central nervous, neurohormonal, cellular and molecular levels
that aim to restore equilibrium [14]. These defence mechanisms can, however, have detrimental
eﬀects on the regulation of nutrient metabolism, the cardiovascular system, and brain function,
if they are overactive or prolonged. Therefore, Abraham et al. [14] suggest that stress can be
seen as a threat to the organism's homeostasis. It is also suggested that insulin resistance (or,
the attenuated eﬀect of insulin in target tissues) may be a common pathway linking stress and
the development of metabolic syndrome and T2DM [14].
Toussaint et al. [54] highlight a number of key issues regarding stresses and their cellular
responses. For example, stresses vary in degree and thus generate diﬀerent degrees of damage,
which may be responsible for accelerated ageing. Cells in turn exert protective eﬀorts in an
attempt to eliminate damages, which induce defence and repair systems. However, with age-
ing, damages accumulate and result ﬁrst in decreases (in the constitutive level or inducibility)
of defences, followed by dysregulation of defence system networks. Secondly, with ageing, a
decrease in energy metabolism is induced, and speciﬁcally its inductibility by stress. This is
undesirable since energy metabolism is a necessity for eﬃcient cell response and survival under
stress conditions. With insulin resistance and glucose intolerance, energy metabolism needs will
most likely not be met timely, despite the supply of accumulated FAs, because the more rapid
stress-stimulated glucose metabolism is now blunted. Interestingly, an in vivo study demon-
strates that FA oxidation in the heart is increased four to eight hours after a dexamethasone12
12Dexamethasone is a potent synthetic glucocorticoid which mimics the action of cortisol and is therefore
frequently used in studies which investigate the eﬀects of stress, glucocorticoids or cortisol in a given system.
Similar to cortisol, dexamethasone acts as an immunosuppressant and anti-inﬂammatory agent.
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injection [23].
Radahmadi [55] reports that stress (with mainly psychological component) exacerbated dia-
betes mellitus in streptozotocin-treated13 rats, and also raised glucose levels signiﬁcantly in
non-diabetic controls.
Abraham et al. [14] propose that stress (even psychosocial factors) can lead to metabolic
perturbation and increase cardiovascular risk via activation of neuroendocrine responses. In
the long run, these neuroendocrine responses may be of signiﬁcance in the development of
insulin resistance and T2DM. For example, high glucocorticoid levels promote storage of lipid
in visceral rather than subcutaneous tissue, and the proinﬂammatory cytokines secreted by
adipocytes are considered to increase oxidants and cell injury.
1.5.4 Glucocorticoid excess and insulin resistance
Cortisol excess is characterised by such phenomena as hypertension, central obesity and glucose
intolerance. These eﬀects of cortisol depend in part on opposing the actions of insulin. Thus,
an induced state of insulin resistance will contribute to the aforementioned phenomena. The
cardiovascular consequences of cortisol excess are described as `protean' [57] and include eleva-
tion of blood pressure, truncal obesity, hyperinsulinaemia, hyperglycaemia, insulin resistance,
and dyslipidaemia. Various studies into glucocorticoid eﬀects on GLUT4 translocation have
been conducted, some of which will be discussed below.
Within the prenatal setting, GLUT1 (the major glucose transporter in the foetal rat heart)
is suppressed at birth whilst GLUT4 takes over as major glucose transporter in the adult. Sim-
ilar to thyroid hormones (in control of this GLUT1-GLUT4 switching in the perinatal period),
cortisol is involved in development. In addition, cortisol may aﬀect GLUT1 expression [58].
Upon analysis of cortisol-treated foetal sheep hearts, mRNA levels of GLUT1 were found to
be reduced, and Lumbers et al. [58] deduced that cortisol may play a role in neonatal GLUT1
suppression. mRNA levels of GR and MR were, however, not aﬀected by cortisol treatment.
Under normal physiological conditions dexamethasone is reported to increase AMPK activ-
13Streptozotocin is a drug that displays selective toxicity to pancreatic, insulin-producing beta cells. The
toxicity is mediated by reactive oxygen species (ROS) [56], and induces diabetes mellitus. In this case a single
intraperitoneal injection was administered and success determined by positively testing for glucose in urine
samples.
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ity which leads to augmented FA oxidation [59], and promotes glucose uptake and glycogen
synthesis [32]. A rat model was employed to investigate eﬀects of glucocorticoid excess on the
sensitivity of glucose transport and metabolism to insulin in skeletal muscle, and results indi-
cated that glucocorticoid excess causes insulin resistance directly by inhibiting insulin-induced
GLUT4 translocation to the sarcolemma [60]. However, total GLUT4 content was not de-
creased by dexamethasone treatment (conﬁrmed by Sakoda et al. [61]), although the capacity
for insulin to recruit the transporters to the membrane was diminished. Based on these results,
Dimitriadis et al. [60] argue that although glucocorticoids may increase lipolysis (suggesting
that increased oxidation of non-esteriﬁed FAs may be the cause of insulin resistance) it may
not be the main mechanism underlying glucocorticoid-induced insulin resistance.
A review by Qi & Rodrigues [23] reports some of the eﬀects that dexamethasone treatment
exerted on insulin signalling, including signiﬁcantly inhibited total mRNA and tyrosine phos-
phorylation of IRS-1, citing Sakoda et al. [61], among others. Giorgino et al. [62] reported a
similar ﬁnding when insulin signalling factors upstream from GLUT4 were investigated. Here,
glucocorticoid-treated skeletal muscle exhibited decreased tyrosine phosphorylation of IRs, due
to a reduction in the pool of receptors undergoing tyrosine phosphorylation. A decline in the
IRS-1 content and reduced serine and/or threonine phosphorylation of IRS-1 was also observed.
Sakoda et al. [61], however, report that even after IRS-1 and PI3K were normalised via IRS-1
overexpression, there was no signiﬁcant improvement of insulin-induced glucose uptake im-
paired by dexamethasone. This ﬁnding led others [23] to speculate that glucocorticoids may
decrease glucose uptake by their inhibition of glucose transport rather than insulin signalling
transduction. In support, a recent study found that dexamethasone may inhibit the activation
of GLUT4 in the cell membrane (of adipocytes) through p38 mitogen-activated protein kinase
(MAPK) signalling [63]. This may correlate with a study that found that cell membrane asso-
ciation of GLUT4 is decreased in the hippocampi of corticosterone-treated (type 1 and type 2)
diabetes rats [64].
Taken together, these data emphasise the capacity of glucocorticoids to inﬂuence the onset
of insulin resistance and related cardiometabolic diseases. Another major player in the aeti-
ology of these diseases is oxidative stress, which can also be induced by glucocorticoids [52].
However, oxidative stress is frequently associated with inﬂammation and may thus be indirectly
downregulated by the potent anti-inﬂammatory eﬀects of glucocorticoids [52].
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1.6 Oxidative stress
Reactive oxygen species (ROS) occur as a result of normal metabolism and exposure to xeno-
biotic compounds [65]. ROS describes short-lived, diﬀusible entities such as hydroxyl (·OH),
alkoxyl (RO·) and peroxyl (ROO·) radicals, as well as (medium lifetime) superoxide (O2·) and
nitroxyl (NO·) radicals functions [66]. ROS also includes non-radicals e.g. hydrogen peroxide
(H2O2) and hydroperoxides (ROOH). Sites of ROS generation within the heart include cardiac
myocytes, endothelial cells and neutrophils [67]. Under normal conditions, ROS may provide
beneﬁcial functions [66]. However, this is another defence mechanism that can be detrimen-
tal to cells if homeostasis is exceedingly perturbed. When the production of reactive oxygen
species overwhelms the intrinsic anti-oxidant defences, oxidative stress can cause indiscriminate
damage including loss of function and even cell death [68].
In the mitochondrial ETC, there are four protein complexes (I, II, III, and IV) situated within
the inner mitochondrial membrane [refer Figure 1.5]. During mitochondrial metabolism elec-
tron donors are generated. The ﬂow of electrons from these electron donors through the ETC
to the ﬁnal electron acceptors constitutes oxidative phosphorylation. For example, if glucose is
Figure 1.5: Superoxide production by the mitochondrial electron transport chain. Figure adapted
from Brownlee [19].
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metabolised via the citric acid cycle, it generates NADH and FADH2 as electron donors. The
main electron donor, NADH, releases electrons to complex I (also known as NADH dehydro-
genase or NADH-coenzyme Q oxidoreductase). FADH2 donates electrons to complex II (which
is also known as succinate dehydrogenase or succinate-Q oxidoreductase). The electrons from
both complexes move to complex III via the intermediate coenzyme Q, and are then transferred
to cytochrome C and complex IV. Finally, the electrons are passed to molecular oxygen which
they reduce to water [19].
The electron transport system is organised such that ATP can be precisely regulated. The
following scenario is based on normal cells. Some of the energy the electrons release is used to
pump protons across the membrane into the intermembrane space by complexes I, III and IV.
A voltage gradient results. ATP synthase utilises the energy from the voltage diﬀerence across
the mitochondrial membrane for ATP synthesis. To keep the rate of ATP generation constant,
the voltage gradient can also be reduced by uncoupling proteins (UCPs) producing heat.
However, in the high-glucose milieu of diabetes, greater glucose oxidation will yield more elec-
tron donors (NADH and FADH2) for entry into the ETC. Consequently, the voltage gradient
across the mitochondrial membrane will increase until a critical threshold is reached, at which
point electron transfer inside complex III is blocked [19]. Electrons will then accumulate at co-
enzyme Q which will donate one electron at a time to molecular oxygen, generating superoxide.
Superoxide can be degraded by the mitochondrial isoform of superoxide dismutase (SOD) to
hydrogen peroxide (H2O2), and this followed by enzymatic conversion to H2O and O2. However,
if homeostasis is perturbed and superﬂuous superoxide is produced, it may have detrimental
consequences.
According to Taegtmeyer et al. [25], the consequences of excess fuel if left unchecked are a
metabolic `disaster' zone in the heart. The build-up of ROS, and metabolic substrates (chieﬂy,
glucose and long-chain FAs) are proposed to cause the greatest damage. Many intracellular
signalling cascades aimed at maintaining homeostasis (with the direct environment) involve
ROS as an important second messenger.
1.6.1 Oxidative stress as a result of psychological stress
Psychosocial and socioeconomic factors interact with biological mechanisms including cogni-
tive, neuroendocrine, metabolic and molecular responses [37]. There is mounting evidence that
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psychological stress can lead to oxidant production and oxidative damage to cellular macro-
molecules, such as proteins, lipids and DNA [49]. When stress is perceived or experienced there
is a change in glucocorticoid regulatory activity of the HPA axis. Chronic tissue exposure to
glucocorticoids may lead to metabolic and vascular changes that could accelerate vascular age-
ing [52]. Furthermore, stress stimulates metabolic pathways that yield ATP to meet increased
energy demands. If these stress-mediated pathways are overstimulated, concomitant increasing
ROS production could activate molecular mechanisms leading to cytotoxicity [49].
1.6.2 Oxidative stress as an underlying cause of metabolic disorders
Oxidative stress is caused by an imbalance between ROS production and the cell's anti-oxidant
capacity to neutralise reactive intermediates and/or repair the resulting damage [65], [69]. Con-
ditions of higher substrate inﬂux such as hyperglycaemia and hyperlipidaemia may bring about
such an imbalance - or `substrate stress' as referred to by Baynes & Thorpe [70] - since the
mitochondrion, which is largely responsible for molecular metabolism, is a critical site of ROS
production.
It is proposed that the pathogenic eﬀect of high glucose is signiﬁcantly mediated via increased
production of ROS and reactive nitrogen species (RNS) [71]. This is suspected to happen in
concert with eﬀects of high FAs. Oxidative stress, resulting from ROS accumulation, is impli-
cated in atherosclerosis, microvascular complications of diabetes, and β-cell failure in T2DM
[37].
According to Sugamura & Keaney [72] there is considerable data portraying ROS and oxidative
stress as key features of cardiovascular diseases including atherosclerosis, hypertension, and
congestive heart failure. By contrast, others [65] note that 1) there is an association between
superﬂuous oxidants and the multifactorial pathogenesis of insulin resistance, and 2) there are
numerous possible sites of ROS production (ROS being implicated in the relationship between
oxidative stress and aetiology of insulin resistance) yet there is surprisingly limited evidence to
support this notion.
One of the mechanisms by which oxidative stress may be a causative factor in the develop-
ment of insulin resistance involves impaired insuling signalling [18] and GLUT4 translocation.
Karnieli & Armoni [73] cite evidence that protracted ROS exposure aﬀects glucose transporter
transcription, i.e. increased GLUT1 levels and a concomitant reduction in GLUT4 gene ex-
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pression.
With regards to dysregulated glucose metabolism, hyperglycaemia has repeatedly been identi-
ﬁed as a cause of superoxide production [69], [74], [75]. In addition, hyperglycaemia-induced
ROS and -RNS are considered to damage macromolecules directly (by oxidising DNA, proteins
and lipids), and indirectly induce tissue damage (by activating cellular, stress-sensitive path-
ways) [71]. Activation of these pathways (including nuclear factor κ-B (NFκ-B), p38 MAPK,
NH2-terminal Jun kinases/stress-activated kinases and hexosamines, inter alia) is associated
with the pathogenesis of insulin resistance.
Oxidative stress has also been identiﬁed as a key factor in hyperglycaemia-induced apopto-
sis in mouse myocardium and rat cardiomyocytes [76]. Since the focus of this research includes
hexosamine production via the HBP, the ﬁndings of a similar study by Rajamani & Essop [77]
are more relevant. The ﬁndings include identiﬁcation of a novel pathway in which oxidative
stress (and the HBP) may play a crucial role in diabetes-related onset of heart disease via
increased myocardial apoptosis. They found that hyperglycaemia induces intensiﬁed oxidative
stress in H9c2 cardiomyoblasts, along with increased HBP activation and O-GlcNAcylation
of the anti-apoptotic protein, BAD. Furthermore, Du et al. [78] found that overproduction
of hyperglycaemia-induced mitochondrial superoxide increases hexosamine synthesis as well as
O-linked glycosylation of Sp1. Sp1 glycosylation activates gene expression that plays a role in
the pathogenesis of diabetic complications. These data provide various mechanisms by which
oxidative stress, and the resulting hexosamine glycosylation, are involved in the development
of metabolic disorders.
Another factor known to increase oxidative stress is lipid overload. Lipid overload occurs
when FA uptake exceeds oxidising capacity and is known to result in elevated triglycerides, ac-
cumulation of lipid metabolites (speciﬁcally, ceramides), endoplasmic stress, and lipid mediated
alterations in membrane function. Excess lipid is lipotoxic in that it results in programmed
cell death, contractile dysfunction and heart failure [25]. Furthermore, superoxide production
is increased by high glucose concentrations while high fat levels elevate both superoxide and
peroxynitrite production [69].
Henriksen et al. [65] suggest that an important goal of future clinical investigations should
involve the development and implementation of anti-oxidant interventions. The latter should
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have improved oral bioavailability and target the critical sites of oxidant overproduction, such
as (skeletal) muscle mitochondria. This suggestion is made in light of increasing evidence in
obesity-associated rat models of oxidative stress and insulin resistance that antioxidant treat-
ments mediate improved glucose tolerance and insulin sensitivity, as well as ameliorate function-
ality of the glucose transport system in skeletal muscle. Sugamura et al. [72] warn, however,
that it is oversimplistic to expect speciﬁc (beneﬁcial) results on cardiovascular disease when
employing a general anti-oxidant strategy, and then reviews the most important sources of
ROS that have been associated with CVD pathology. They include the mitochondrial respira-
tory chain, nicotinamide adenine dinucleotide phosphate (NADPH) oxidases, xanthine oxidase,
lipoxygenase, uncoupled nitric oxide synthase (NOS), and myeloperoxidase (MPO). Others [65]
highlight mitochondrial hydrogen peroxide and NADPH oxidases as relevant to the aetiology of
insulin resistance. Notably, inhibition of xanthine oxidase has recently been reported to reduce
hyperglycaemia-induced oxidative stress, and ameliorate mitochondrial alterations in diabetic
mice [79].
In order to further understand the molecular relationship between oxidative stress, glucocorti-
coids and stress, insulin resistance as well as the metabolic syndrome, and how these factors
contribute to the pathophysiology of the aforementioned diseases, greater insight is required
into damaging hyperglycaemia-activated pathways, speciﬁcally the HBP.
1.7 Damaging pathways activated by hyperglycaemia
One of the risk factors of the metabolic syndrome is elevated blood glucose levels, a symptom
which is exacerbated by insulin resistance i.e. decreased glucose uptake. In a hyperglycaemic
setting such as diabetes, cells are bathed in glucose. In an attempt to maintain constant glucose
levels and homeostasis, cells reduce their glucose uptake. Certain cell types are, however, more
proﬁcient at this than others, leaving some cells subsets more vulnerable to hyperglycaemia-
induced `tissue' damage [19]. Retinal capillary endothelial cells, mesangial cells in the renal
glomerulus, as well as neurons and Schwann cells are among the vulnerable cell types, which
explains the retinopathy, nephropathy and neuropathy complications widely associated with
diabetes.
Glycolysis typically consumes the majority of glucose entering the cell, but there are pathways or
mechanisms that branch oﬀ, diverting (excess) glucose ﬂux. Increased hyperglycaemia-induced
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superoxide causes glycolytic intermediates to be shunted into the major pathways of hyper-
glycaemic damage [80]. The four major implicated molecular mechanisms include increased
polyol pathway ﬂux, increased activation of the protein kinase C (PKC) pathway, increased
formation of advanced glycation end products (AGEs), as well as increased ﬂux through the
HBP [81] [refer Figure 1.6].
1.7.1 Polyol pathway
Although many theories have been proposed to explain the harmful eﬀects of hyperglycaemia,
one of the oldest theories involves the polyol pathway [82], described for the ﬁrst time in
peripheral nerve in 1966 [83]. One of the key aldo-keto reductase enzymes of this pathway,
aldose reductase, is found in tissues such as retina, lens, glomerulus, nerve, and vascular cells.14
These reductase enzymes, with NADPH, can reduce a large variety of carbonyl compounds to
their sugar alcohols (polyols) [74]. Similarly, aldose reductase normally functions to reduce toxic
aldehydes in the cell to inactive alchohols, but it also reduces excess glucose to sorbitol which
undergoes oxidation to fructose [19] by the enzyme, sorbitol dehydrogenase (SDH). Apart from
being the cofactor in the aldose reductase reaction, NADPH is also the essential cofactor for the
production of reduced glutathione (GSH), an important intracellular anti-oxidant. Thus, in the
context of hyperglycaemia the process of reducing high intracellular glucose depletes NADPH,
decreasing the production of GSH, leaving the cell more vulnerable to oxidative stress [19].
Elevated ﬂux of the polyol pathway has been associated with decreased myoinositol uptake,
attenuated sodium/potassium adenosine triphosphatase (Na+/K+ ATPase) activity, and in-
creased production of vasodilatory prostaglandins in many of the target tissues of hyperglycaemia-
induced damage [82].
1.7.2 PKC pathway
There are at least 11 isoforms of PKC and they are widely distributed in mammalian tissues.
Diacylglycerol (DAG) is an essential activating cofactor of the classic isoforms of PKC-β, -δ,
and -α [74]. The activity of the classic isoforms are dependent on both Ca2+ ions and phos-
phatidylserine, while DAG enhances it.
14The retina, glomeruli and neuronal tissue are sites where the hyperglycaemia-induced microvascular com-
plications of diabetes are clearly visible [82].
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Figure 1.6: Hyperglycaemia-activated pathways include AGE formation, PKC activation, the polyol
and hexosamine biosynthetic pathways (adapted from Rolo & Palmeira [81]). These are known to
be damaging during hyperglycaemia. AGE, advanced glycation end product; BP, bisphosphate;
DAG, diacylglycerol; GAPDH, glyceraldehyde-3-phosphate dehydrogenase ; GFAT, glutamine:fructose-
6-phosphate amidotransferase; GSH, glutathione (reduced); GSSG, glutathione (oxidised); HK,
hexokinase; LDH, lactate dehydrogenase; NAD+, nicotinamide adenine dinucleotide (oxidised);
NADH, nicotinamide adenine dinucleotide (reduced); NADP+, nicotinamide adenine dinucleotide
phosphate (oxidised); NADPH, nicotinamide adenine dinucleotide phosphate (reduced); NAG, N-
acetylglucosamine; P, phosphate; PDH, pyruvate dehydrogenase; PFK, phosphofructokinase; PGI,
phosphoglycerate isomerase; PGK phosphoglycerate kinase; PK, pyruvate kinase; PKC, protein kinase
C; TIM, triose phosphate isomerase; UDP, Uridine diphosphate.
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Intracellular hyperglycaemia enhances de novo synthesis of DAG. This is achieved by the reduc-
tion of glycolytic intermediate dihydroxyacetone phosphate (DHAP) to glycerol-3-phosphate
and stepwise acylation [75]. Protracted and superﬂuous activation of several PKC isoforms
may also lead to ROS-mediated means of tissue damage. Furthermore, since increased ROS
inhibits activity of the glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
[84], intracellular levels of the DAG precursor, triose phosphate, are elevated which would ulti-
mately increase PKC activation. Moreover, hyperglycaemia-mediated PKC isoforms (β and δ)
may also result in a variety of eﬀects on gene expression [19].
1.7.3 AGE formation
Glucose and other glycating compounds - derived from both glucose and increased fatty acid
oxidation - react non-enzymatically to form AGEs [74]. AGEs can arise by intracellular auto-
oxidation of glucose to glyoxal, decomposition of the Amadori product (glucose-derived 1-amino-
1-deoxyfructose lysine adducts) to 3-deoxyglucosone, and fragmentation of glyceraldehyde-3-
phosphate and dihydroxyacetone phosphate to methylglyoxal. When these reactive intracellular
dicarbonyls (glyoxal, methylglyoxal and 3-deoxyglucosone) react with amino groups of intra-
cellular and extracellular proteins, AGEs form [75].
Sugimoto et al. [85] proposed that oxidative stress mediates hyperglycaemia-induced cell injury,
via signalling pathways involving an interaction between exogenous AGEs and their receptors
(RAGEs). Subsequently, Coughlan et al. [86] conﬁrmed that AGE-RAGE interactions disrupt
the mitochondrial respiratory chain under normoglycemic conditions. Under hyperglycaemic
conditions, RAGE-induced cytosolic ROS promoted signiﬁcant generation of mitochondrial
superoxide (at the level of complex I). There is also a diﬀerence between acute hyperglycaemia,
and chronic diabetes which exhibits signiﬁcantly elevated levels of superoxide production in
renal mitochondria [87]. AGEs are also known to increase NFκ-B activity, the production of
vasoactive factors and cytokines such as interleukin-1 (IL-1), and -6 (IL-6), and tumour necrosis
factor-α (TNF-α) [88].
1.7.4 The hexosamine biosynthetic pathway
The HBP was ﬁrst described by Torres & Hart in 1984 [89], and its key role in regulating the
insulin-responsive glucose transport system was acknowledged as early as 1991 [90]. It has been
shown that one of the most rapid cellular responses from a variety of unrelated sources is an
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increase in O-GlcNAcylation on many proteins [91].
In this pathway, fructose-6-phosphate is diverted from glycolysis as substrate to the rate-
limiting enzyme of the HBP; glutamine:fructose-6-phosphate amidotransferase (GFAT) [74].
GFAT converts fructose-6-phosphate to glucosamine 6-phosphate. The fate of glucose entering
this pathway is conversion to uridine diphospho-β-N-acetylglucosamine (UDP-GlcNAc) which
is used by O-GlcNAc transferase (OGT)15 in the biosynthesis of O-GlcNAc-modiﬁed proteins.
In the reverse reaction, O-GlcNAcase (OGA) catalyses the removal of GlcNAc moeities from
modiﬁed proteins.16 Pharmacological inhibition of OGA, speciﬁcally by PUGNAc, is regarded
an invaluable tool for examining cellular functions of O-GlcNAc [93]. Figure 1.7 shows struc-
tures of PUGNAc interacting with its OGA binding site.
Excess glucose ﬂux into the HBP has been linked to the onset of insulin resistance and vascular
complications of diabetes [94]. Furthermore, dysregulation of O-GlcNAcylation has been as-
sociated with various chronic disease processes apart from diabetes and diabetic complications
[95], including ageing, neurodegeneration, cancer, and AIDS [45]. Another widely recognised
causal link between diabetes and diabetic complications is hyperglycaemia that results from
uncontrolled glucose regulation. Brownlee's laboratory postulates that hyperglycaemia which
results in upstream accumulation of glycolytic metabolites, such as fructose-6-phosphate, may
augment ﬂux through the HBP [96]. Rajamani & Essop [77] have shown in H9c2 rat cardiomy-
oblasts that hyperglycaemia-induced activation of the HBP results in cell death and thus tissue
damage .
1.7.4.1 Involvement of HBP in insulin resistance and diabetes
Flux of fructose-6-phosphate into the HBP is increased by hyperglycaemia and insulin resistance-
induced excess fatty acid oxidation, thereby contributing to the pathogenesis of diabetic compli-
cations [19], [78]. The requirement for glucosamine in the pathophysiology of insulin resistance
in adipocytes [90] strongly implicates the HBP in the aetiology of the disease. This is com-
pounded by the ﬁnding that GFAT inhibitors improved insulin-stimulated glucose uptake. Fur-
thermore, UDP-GlcNAc levels were considerably increased in rats administered lipid emulsion
15Aside from sensitivity to the availability of UDP-GlcNAc, OGT is also sensitive to insulin. Upon insulin
stimulation OGT associates to cell membrane phosphoinositides, and the IR directly tyrosine phosphorylates
the enzyme, thereby activating it [92].
16OGT and OGA are highly conserved enzymes [44] and animals usually only have one gene encoding OGT
[92].
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Figure 1.7: Schimpl et al. [93] presented these structural diagrams of Oceanicola granulosus OGA
(OgOGA) and PUGNAc. [A] The light blue on this surface view of OgOGA represents sequence
conservation among metazoan OGAs, whilst the dark blue represents the same amongst metazoan
OGAs+OgOGA. PUGNAc is shown (in green) with additional ordered loops from the apo-structure.
[B] The active site of the OgOGA-PUGNAc represented in a stick model. The ligands are shown
as sticks with carbons in green, and hydrogen bonds drawn as broken, black lines. Hydrogen bonds
to/from the protein backbone amides are depicted as originating from the Cα. Residues of the OgOGA
active site are labelled in black, with the equivalent hOGA residues in blue.
infusions, prior to the onset of insulin resistance. Insulin resistance onset was also promoted in
adipocytes by competitive inhibition of OGA, the enzyme responsible for O-GlcNAc removal
[97].
Oxidative stress increases ﬂux through metabolic circuits such as the HBP [69]. The HBP
modiﬁes numerous target proteins, including IRS, Akt and GLUT4 [98] but when modiﬁcation
becomes dysregulated adverse consequences result. Chronic HBP activation increases AMPK
activity (in adipocytes) [99] which increases FA oxidation, possibly leading to greater oxidative
stress.
Interestingly, OGT is highly concentrated in mitochondria, which Love et al. [100] ascribe
to mitochondrial OGT (mOGT) being the smallest (103 kDa) of the three known isoforms.
They also found that it localises to the inner mitochondrial membrane. A recent a study
showed that increased O-linked glycosylation of mitochondrial proteins, including key proteins
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 1. INTRODUCTION 29
of the ETC, is involved in diabetes-associated mitochondrial dysfunction in cardiomyocytes
[101]. In addition to impaired activity of complexes I, III, and IV of the ETC, high O-GlcNAc
levels are also associated with lower mitochondrial Ca2+ and cellular ATP content. Ca2+ ﬂux
into cardiomyocytes is diminished due to hyper-O-GlcNAcylation of the nuclear transcription
factor Sp1 and the resulting decrease in sarcoendoplasmic reticulum Ca2+-ATPase (SERCA2a)
gene expression [101]. Furthermore, Ca2+ plays an important regulatory role in cellular events,
including GLUT4 gene expression. High cytosolic Ca2+ increases GLUT4 expression via the
activation of Ca2+/calmodulin-dependent protein kinase (CaMK) [73]. The adverse eﬀects of
the HBP-induced Ca2+ reduction are multiple; including possible disruption of mitochondrial
membrane potential, and diminished GLUT4 content.
Chronically activated HBP ﬂux is associated with impaired GLUT4 translocation [102], and
thus with insulin resistance aetiology. Upstream of GLUT4 translocation, upregulation of the
HBP reportedly leads to impaired IRS-PI3K-Akt signalling [103]. In a model of GFAT over-
expression, mice developed insulin resistance and muscle glucose disposal rates decreased which
was linked to reduced levels of GLUT4 [104].
Collectively, these studies portray chronically elevated HBP ﬂux as having far-reaching adverse
eﬀects on regulatory factors in the onset of insulin intolerance. Dysregulation of transcription
factors, glucose transporter signalling, as well as mitochondrial respiratory processes and the
resulting oxidative stress are highlighted as key targets of the HBP in the context of insulin
resistance development.
1.7.4.2 Acute versus chronic HBP activation
It has been suggested that short-term increases in O-GlcNAc modiﬁcation of proteins may be
important for cellular survival [91], and that acute increases inO-GlcNAcylation is cardioprotec-
tive [95]. For example Liu et al. [105] showed that speciﬁcally increasing O-GlcNAcylation dur-
ing reperfusion is suﬃcient for cardioprotection. In doing so glucosamine and O-(2-acetamido-
2-deoxy-D-glucopyranosylidene)amino-N-phenylcarbamate (PUGNAc, a non-speciﬁc inhibitor
of O-GlcNAc removal) were identiﬁed as potentially useful cardioprotective agents.
In contrast to the school of thought that O-GlcNAc is a protective agent, it has also been
shown that chronic activation of the HBP negatively aﬀects cardiac function in diabetic models
[106], and contributes directly to cardiomyopathy [92]. A similar paradox exists between the
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roles of O-GlcNAc in diabetes and neurodegeneration where, in contrast to diabetes, higher O-
GlcNAcylation appears to prevent disease and lower O-GlcNAcylation in the brain contributes
to neuronal cell death [92]. In other words, this same pathway can have diﬀerent, even oppos-
ing, functional outcomes, depending on the conditions of or surrounding its activation. This
paradox demands further investigation since O-GlcNAc has a multitude of target proteins, and
complex interplay exists between 1) the cellular processes that it regulates and 2) crosstalk with
phosphorylation [107]. This has been described more eloquently by Hart et al. [92] using the
analogy of an electrical circuit; `. . . if phosphorylation events represent `microswitches', which
turn on or oﬀ protein activity, O-GlcNAcylation could be thought of as a `rheostat' tuning the
pathways and processes to accommodate nutrient status and cellular stress.'
1.7.5 Summarising hyperglycaemia-activated pathways
Brownlee [19] puts forth a unifying hypothesis, postulating that the polyol, PKC, AGE and HBP
pathways are activated due to impaired GAPDH activity. Hyperglycaemia induces increases of
inner mitochondrial membrane potential which results in intensiﬁed mitochondrial superoxide
production [75], as well as single strand DNA damage which elicits the reparitive response of
poly(ADP-ribose) polymerase (PARP) [108]. GAPDH is inhibited by both hyperglycaemia-
induced mitochondrial superoxide and the resulting activation of PARP [19], [84].
Furthermore, it has been shown that speciﬁc inhibitors of each of these pathways ameliorate
various diabetes abnormalities in cell culture or animal models [74]. Although ROS emerges
as a common element, it has not been clariﬁed whether a common cause(s) underlies these
processes, or if they are all interconnected.
1.8 Research problem
Despite multipronged approaches to increase awareness of metabolic diseases, the incidence of
these diseases worldwide remains extremely high. Clearly the words of Bernard (1878), Can-
non (1939), Selye (1956), and Taegtmeyer & Stanley (2011), who all emphasise (homeostatic)
balance as a key factor in health and survival, are not heeded. Although some may be able
to reverse detrimental eﬀects of poor lifestyle habits and choices with regards to diet, physical
activity, and stress, it may be too late for others. Urgent action is needed to curb the growth of
this epidemic. More speciﬁcally, elucidation of mechanisms underlying these diseases is required
to help rescue patients from otherwise irreparable damage.
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Interestingly, it has been shown (at cellular level) that O-GlcNAc levels are increased in re-
sponse to stress [95]. In fact, the earliest detected response to cellular stress in every mammalian
cell type examined so far is a rapid and global increase in O-GlcNAcylation on many proteins
[109]. Stress-induced increases in O-GlcNAc return to normal after 24 to 48 hours [91]. Based
on this information, the HBP plays a pivotal role in this research problem, and as such, is the
major research focus.
1.9 Hypothesis
We hypothesise that the synthetic glucocorticoid, dexamethasone, would increase oxidative
stress and HBP ﬂux. Through greater O-GlcNAcylation of the insulin signalling pathway,
GLUT4 translocation would be attenuated, contributing to the onset of myocardial insulin
resistance.
1.10 Aims
1. Establish the HL-1 cardiac myocyte cell line in our laboratory
2. Establish an in vitro model for dexamethasone-treated cardiac cells
3. Assess oxidative stress in response to dexamethasone treatment
4. Evaluate the degree of O-GlcNAcylation in response to dexamethasone treatment
5. Determine the extent of GLUT4 translocation upon dexamethasone treatment
Stellenbosch University http://scholar.sun.ac.za
Chapter 2
Materials and Methods
2.1 Cell culture
The initial aim was to assess the eﬀect of the glucocorticoid, dexamethasone (a synthetic cortisol
analogue), on HBP ﬂux and explore whether it had any link to cardiometabolic pathophysiology.
An immortalised cardiac-derived cell line, namely HL-1 cardiomyocytes, was kindly donated by
Professor William C. Claycomb1 for this purpose. Establishing this cell line was no simple task
as the cells are very sensitive to changes in the environment, speciﬁcally carbon dioxide (CO2)
levels. HL-1 cells also have a very unique trait which requires great care, i.e. the ability to
contract in culture. In light of this, a large part of this study involved optimisation of cell
culturing conditions for HL-1 cells.
2.1.1 Establishing the protocol for HL-1 cell culture
The HL-1 cell line is derived from AT-1 cardiac myocytes, and has been determined to be a
homogenous population at passages beyond 30 [110]. These cells bear two important charac-
teristics, namely spontaneous action potentials and contractions they display in culture [111].
HL-1 cells can be serially passaged for more than two hundred times and retain their ability to
contract together with the cardiomyocyte phenotype.
The HL-1 cell line, at passage 63, was donated to the Cardio-Metabolic Research Group housed
within the Department of Physiological Sciences at Stellenbosch University (the ﬁrst research
group to establish this cell line in South Africa) by Professor Claycomb. A detailed protocol
1Department of Biochemistry and Molecular Biology, LSU Health Sciences Centre, New Orleans, USA.
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for culturing HL-1 cells can be found in Appendix A under Growth and care of HL-1 cardio-
myocytes. The growth of the cells was tracked from seeding to near-conﬂuency [refer Figure 2.2].
After the cells were ﬁrst received (at passage 63) live in two T25 ﬂasks, at ambient temper-
ature, they were immediately placed in an incubator with a humidiﬁed atmosphere (95% air,
5% CO2) at 37°C and allowed time to acclimatise. It was recommended that cells be passaged
[refer Passaging in Appendix A.6] only once they reached conﬂuency (refer Figure 2.1), soon
after their arrival.
Figure 2.1: HL-1 cells when conﬂuent ∼ two days after seed-
ing roughly one million cells in a T25 ﬂask. The image was
acquired with an Olympus CKX41 light microscope using a
10×/0.25 objective.
One of the T25 ﬂasks would be passaged in coated ﬂasks [Appendix A.4.2] and maintained as
a `working' set of cells, while the other would be cultured for the purpose of freezing cells and
to ensure a build-up of `cell stocks'.
 `Working' set of cells: The ﬁrst T25 ﬂask was split 1:2, resulting in two T25 ﬂasks
(Greiner, Kremsmünster, Austria).
 `Cell stocks': The other T25 was split 1:3, into one T75 ﬂask. Once the cells in this ﬂask
were conﬂuent, it was split 1:2 into two T75 (Greiner, Kremsmünster, Austria) ﬂasks, and
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this process was repeated. When the four T75 ﬂasks reached conﬂuency they were frozen
[protocol can be viewed in Appendix A.7 under Freezing ].
Cells were cultured in T75 culture ﬂasks with Claycomb medium (12103C, Batch 8A0177,
Sigma-Aldrich, Steinheim, Germany) supplemented with 10% foetal bovine serum (12103C,
Batch 8A0177, SAFC Biosciences, KS), 2 mM L-glutamine (G7513, Sigma-Aldrich, Steinheim,
Germany), 0.1 mM norepinephrine [(±)arterenol](A0937, Sigma-Aldrich, Steinheim, Germany)
and penicillin-streptomycin (100 U/ml-100 µg/ml), (P4333, Sigma-Aldrich, Steinheim, Germany)
as instructed [refer Table A.2]. The cells were grown [Appendix A.5] in a humidiﬁed atmosphere
(95% air, 5% CO2 at 37°C). HL-1 cells should be grown to 100% conﬂuency as visible in Figure
2.22 before passaging [Appendix A.6].
2.1.2 Pharmacological treatments
In an attempt to manipulate or simulate various responses, some pharmacological treatments
were administered to the cells. In order to elicit a stress-response, the synthetic analogue for
cortisol, dexamethasone (D4902, Sigma-Aldrich, Steinheim, Germany), was used. α-cyano 4-
hydroxyl cinnamic acid (OHCA), (Sigma-Aldrich, Steinheim, Germany), a previously described
anti-oxidant, was used at a concentration of 250 µM as described [69]. PUGNAc (CarboGen
Labs, Aarau, Switzerland) is a known inhibitor of OGA [refer Figure 1.7], the enzyme respon-
sible for the removal of O-GlcNAc moieties from proteins. Preventing the activity of OGA is
essential when determining the degree of O-GlcNAcylation, which makes PUGNAc (adminis-
tered at 50 µM) a key treatment for Western blotting analysis. Lastly, insulin was administered
to the cells after a period of serum starvation in order to stimulate the translocation of the
glucose transporter, GLUT4, from storage vesicles in the cytosol to the sarcolemma. Insulin
was administered at 300 nM as was previously done in a similar study [28].
2.2 Experimental protocol for analysis after
dexamethasone treatment
In order to investigate the eﬀect of cortisol-like glucocorticoids on HBP ﬂux, an in vitro model
was established. Here, HL-1 cells were treated with various doses of dexamethasone, after which
O-GlcNAc and ROS levels were measured by ﬂow cytometry [Figure 2.3].
2Images of the HL-cells growing were captured with a CKX41 light microscope (Olympus Coorporation,
Tokyo, Japan) using a 10×/0.25 objective.
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Figure 2.2: Images showing the progress of HL-1 cells when ∼ one million cells are seeded in a T25
ﬂask. [A] Immediately after seeding cells started settling to the base of the ﬂask; [B] after 40 minutes a
number of cells had settled on the base of the ﬂask; [C] three hours after cells were seeded they started
adhering to the coated surface of the ﬂask; [D] after 6 hours the cells plated and numbers visibly
increased; [E] 24 hours after seeding the number of cells had increased greatly; [F] after 48 hours, cells
were nearly conﬂuent. A 10×/0.25 objective was used.
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Figure 2.3: This diagram provides an overview of the experimental methods carried out and repre-
sented in this thesis in order to investigate eﬀects of the synthetic glucocorticoid, dexamethasone, on
HL-1 cardiomyocytes.
2.2.1 Flow cytometry
Flow cytometry is a quantitative technique used for counting microscopic particles such as cells,
and it allows for the multiparametric analysis of the physical and/or chemical characteristics
of thousands of particles per second based on their ﬂuorescent properties. The particles are
suspended in ﬂuid and pass through lasers at a point of iso-electric focusing. A photomultiplier
tube (PMT) detects the emitted light. An optical-to-electronic coupling system records how
the cell or particle scatters incident light and emits ﬂuorescence. The characteristics measured
include a particle's relative size, granularity or internal complexity, and ﬂuorescence intensity.
Molecules of interest can be detected either by staining cells with a ﬂuorescent dye or by the
use of appropriately selected antibodies.
A FACS Aria I ﬂow cytometer (Becton-Dickinson Biosciences, San Jose, CA) was used for all
ﬂow cytometry analyses. A minimum of 5, 000 events per sample were recorded. Excitation of
all ﬂuorochromes (FITC and PE-TxRed) at 488 nm was achieved with a solid state sapphire
laser. FITC emission was detected by a 502 long pass (LP) and 530/30 band pass (BP) ﬁlter.
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PE-TxRed ﬂuorescence was detected by a 610 LP and 616/23 BP ﬁlter. The geometric mean of
the ﬂuorescence intensity signal was measured on the intensity histogram, utilising FACS Diva
6.1 software (Becton-Dickinson Biosciences, San Jose, CA).
2.2.2 Flow cytometric measurement of ROS
Dihydrodichloroﬂuorescein diacetate (H2DCFDA), (Invitrogen, Carlsbad, CA) is a dye used for
live staining. It is a green ﬂuorescing, ﬂuorescein-based, ﬂuorophore used for the detection of
ROS. FITC ﬂuorescence is emitted (upon excitation) and the ﬂuorescence intensity can be used
as a measure of the degree of ROS within the system. DCF is used to measure general ROS
since it is sensitive to many types of ROS, including superoxide, oxidised glutathione, nitric
oxide, and peroxynitrite.
HL-1 cells were subcultured in T25 ﬂasks (Greiner, Kremsünster, Austria), about one million
cells per ﬂask, and incubated with 3 ml of supplemented Claycomb media [Appendix A.1] for 48
hours at 37°C under a humidiﬁed atmosphere of 95% air and 5% CO2. As previously shown in
Figure 2.2, cells are nearly conﬂuent after 48 hours. Thereafter, treatment with dexamethasone
for 2, 3, and 4 hours was administered as indicated in Figure 2.4.
2.2.2.1 Preparing cells for ﬂow cytometry
After treatment with dexamethasone each ﬂask was washed with calcium-free, magnesium-free
Dulbecco's Phosphate-Buﬀered Saline (PBS) (D8537, Sigma-Aldrich, Germany) and trypsinised
with 0.05% Trypsin-EDTA (T3924, Sigma-Aldrich, Germany). Trypsin was inhibited with a
soybean trypsin inhibitor (T6522, Sigma-Aldrich, Germany) in a 1:1 ratio. Each ﬂask was
rinsed with wash medium (Claycomb medium supplemented with 5% FBS and 1% penicillin-
streptomycin) and the cells from each ﬂask were transferred to 15 ml conical tubes (SPL Life
Sciences, Korea) to be centrifuged at 500×g for 5 minutes in a Digicen 20-R centrifuge (Orto
Alresa, Spain).
H2DCFDA was dissolved in distilled water to make up a 1 M stock from which 10 mM aliquots
were made by diluting 10 µl of the stock in 990 µl of DMSO. For the working solution, the
10 mM dye was diluted 1:200 in PBS. When working with the ROS dye, great care was taken
to handle the cells (that were still viable) very gently at every step so as not to agitate them
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Figure 2.4: This diagram provides an overview of experimental protocol and treatment groups used
for measurement of ROS. There are nine diﬀerent dexamethasone treatments which can be compared
to the untreated control. Then there is a staining control so that autoﬂuorescence can be subtracted.
The positive control is treated with hydrogen peroxide (H2O2) to conﬁrm the activity of the H2DCFDA
ROS dye, and give a relative indication of a positive signal. Dex; dexamethasone.
unnecessarily in order to limit the production of false signal.
After cells were trypsinised and centrifuged, the pellet was treated with 1 ml of the H2DCFDA
ROS dye working solution. The live cell suspension was incubated in the dark for 30 minutes
at 37°C. This process needs to be carried out in the dark since the cleaved DCF is a ﬂuorescent
substrate and any external light aﬀects the signal. The cells were then washed [refer Appendix
C.1] with 2 ml of warm PBS and the dye removed. Subsequenty, the pelleted cells were resus-
pended in warm PBS and transferred to ﬂow cytometry tubes for ﬂow cytometric analysis. The
cells were then run through the FACS ARIA 1 ﬂow cytometer and population data obtained.
Cells not stained with the ROS dye served as negative control, whilst stained cells incubated
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with 100 µl 30% w/v H2O2 for 10 minutes served as the positive control. There was also a
staining control (to detect autoﬂourescence) which contained cells that were neither treated
nor stained.
2.2.3 Flow cytometric measurement of O-GlcNAc
Primary antibodies have a high aﬃnity for unique epitopes, and secondary antibodies bind to
primary antibodies or antibody fragments (such as the Fc or Fab regions). Secondary antibod-
ies are usually labelled with probes, and for ﬂow cytometric application these are ﬂuorophores.
When O-GlcNAc is bound by its primary antibody, and this in turn bound by a ﬂuorescent
secondary antibody, such as R-phycoerythrin-conjugated Texas Red (PE-TxRed), (Jackson
Immunoresearch, West Grove, PA). The greater the ﬂuorescence intensity, the more protein
present.
HL-1 cells were subcultured and about one million cells were seeded per T25 ﬂask and in-
cubated with 3 ml of supplemented Claycomb media [Appendix A.1] for 48 hours at 37°C
under an atmosphere of 95% air and 5% CO2. Cells were then treated with dexamethasone for
2, 3, and 4 hours as indicated [Figure 2.5].
Flasks were washed with warm PBS, and cells were trypsinised and pelleted by centrifugation
[refer Section 2.2.2.1]. All samples were permeabilised with 200 µl ice cold methanol-acetone
(1:1) to facilitate intracellular probing by antibodies, and then incubated on ice, or at 4°C for
10 minutes before being washed with PBS. This was followed by a 20 minute blocking step
at room temperature with 200 µl of 5% donkey serum (D9663, Sigma-Aldrich, St Louis, MO)
made up in PBS. After an additional centrifugation step (500×g for 5 minutes) the serum was
aspirated, and monoclonal primary antibody (anti-O-GlcNAc, CTD110.6, Santa Cruz Biotech-
nology, CA) added to all samples save the staining control, to which only PBS was added.
Upon the addition of 200 µl primary antibody per tube (1:200 dilution in PBS), cells were
incubated in the dark at room temperature for at least 90 minutes. Cells were washed with
PBS before addition of 200 µl of secondary antibody, PE-Texas Red (1:200 in PBS), followed
by a 30 minute incubation step at room temperature in the dark, and a ﬁnal washing step.
[Note comment on washing steps under Flow cytometry in Appendix C.1.]
Cells were suspended in warm PBS and transferred to ﬂow cytometry tubes for ﬂow cytometric
analysis [refer Section 2.2.1]. For each condition investigated, three independent experiments
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Figure 2.5: This diagram provides an overview of experimental protocol and treatment groups used
for measurement of O-GlcNAc. The staining control is stained with the secondary antibody only (no
primary antibody) and serves as a guide for the subtraction of non-speciﬁc ﬂuorescence. The untreated
control provides a baseline with which to compare the nine dexamethasone-treated samples. 1° ab;
primary antibody. Dex; dexamethasone.
were conducted. In order to analyse the data, the geometric mean of the ﬂuorescence intensity
of a cell population was used to represent the numerical value of the experiment.
2.3 Measurement of O-GlcNAcylation by Western
blotting analysis
In addition to ﬂow cytometry, Western blotting was used to assess the overall degree of O-
GlcNAcylation of cells treated with dexamethasone for 2, 3, and 4 hours, respectively.
2.3.1 Cell culture, pharmacological treatments, and lysate collection
Cells were cultured in T25 ﬂasks, with a seeding density of ∼ 106 cells per ﬂask, for 2 days
before administering treatments (dexamethasone ± OHCA). Following treatment [Figure 2.6],
cells were harvested and lysates were prepared [refer Appendices D.1 and D.2].
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Figure 2.6: Overview of treatment protocol prior to Western blotting. The untreated control serves
as a reference to which dexamethasone- and OHCA-treated groups can be compared. Dex; dexametha-
sone. OHCA; α-cyano 4-hydroxyl cinnamic acid.
2.3.2 Preparing samples for Western blotting
The protein content of lysate samples was determined using the Bradford method [Appendix
D.3]. To facilitate protein determination a standard curve was prepared with bovine serum
albumin (BSA) shown in Table D.2 [Appendix D.3]. Once protein content of the lysates had
been established, samples (commonly known as `blues' due to the Coomassie Brilliant Blue
stain in the sample buﬀer) were prepared for sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE) [refer Sample preparation for SDS-PAGE in Appendix D.4].
2.3.3 Gels
Polyacrylamide gels were prepared for protein separation by electrophoresis as described in
Appendix D.5. 10% resolving gels were used with 5% stacking gels [Table D.3, Appendix D.5].
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2.3.4 Electrophoresis
The samples (prepared as discussed in Appendix D.4) were loaded onto 10-well gels along with
a molecular weight marker (Protein-Marker IV, 27-2110, peqGOLD Biotechnologie GmbH,
Erlangen, Germany) and electrophoresis initially carried out at 80 V for 10 minutes, followed
by a further ∼ 80 minutes at 100 V [refer Appendix D.5].
2.3.5 Electrotransfer
The process of electrotransfer [refer Appendix D.6] from gel to membrane was carried out on
semi-dry transfer apparatus at 15 V and 0.5 A for ∼ 80 minutes. A PVDF membrane (0.45 µm
Biotrace PVDF, 66543, PALL Corporation, Life Sciences, Pensacola, FL) was used although
nitrocellulose membranes also work well.
2.3.6 Probing the membrane
The membrane was washed with TBS-T and non-speciﬁc binding blocked with 1% BSA. The
length of blocking depends on the protein(s) of interest and the antibodies (and antibody con-
centrations) being used [Appendix D.7]. When probing for O-GlcNAc [Appendix D.7.3], the
CTD110.6 primary antibody was used in a 1:1000 dilution in TBS-T. The peroxidase conju-
gated, goat anti-mouse antibody (31440, Thermo Scientiﬁc, Rockford, IL) was used as secondary
in a 1:4000 dilution.
The rabbit, β-actin primary antibody (4976S, Cell Signalling Technology, Boston, MA) was used
in a 1:1000 dilution when probing for β-actin [Appendix D.7.4], and bound by a 1:4000 dilution
of goat anti-rabbit, peroxidase conjugated secondary (611 1302, Rockland Immunochemicals,
PA, USA). β-actin is a protein that is widely distributed throughout all eukaryotic cells and is
therefore commonly used as a loading control in assays such as Western blotting.3
2.3.7 Developing the membrane
Membranes were developed as described in Appendix D.8. β-actin blots were usually exposed
for about 5 seconds whereas O-GlcNAc blots were exposed for approximately 1 minute.
3It should be noted that arguments have been made against the reliability of β-actin as a loading control,
particularly in the case of higher total protein loads as required for detecting proteins of low abundance [112].
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2.3.8 Densitometry
The developed ﬁlm was scanned with an HP Scanjet 3500c scanner (Hewlett packard, Palo Alto,
CA) and Un-Scan-It Gel 5.1 software (Silk software, Orem, UT) was used to digitise images
and perform densitometric analysis. Each lane was analysed separately and normalised to the
densitometry value of the corresponding β-actin. Relative diﬀerences in protein expression were
assessed statistically using the normalised densitometric value.
2.4 Experimental protocol for the assessment of GLUT4
translocation
2.4.1 Transfections
To explore the potential eﬀect of dexamethasone on the translocation of GLUT4 to the sarco-
lemma, HL-1 cells were transfected with a haemagglutinin (HA)-tagged GLUT4-GFP con-
struct.4 The GLUT4 DNA construct contains a sequence coding for green ﬂuorescent protein
(GFP) attached at the C-terminal. This allows the translocation of the GLUT4 to be tracked
by monitoring the distribution of the GFP within the cell and at the plasma membrane. The
fusion protein is tagged with an HA epitope in the ﬁrst exofacial loop of GLUT4 which enables
the exposure of the GLUT4 to the extracellular surroundings of the cell to be determined in a
quantitative manner.
The transfected HL-1 cells (after being ﬁxed, but not permeabilised) were stained with an
antibody against HA [Figure 2.7]. By measuring the total cellular GFP ﬂuorescence, the ex-
pression level of GLUT4 was determined. With this knowledge the surface level of GLUT4
(quantiﬁed by the ﬂuorescence of HA antibody) was normalised to the total cellular expression
of the protein [113].
HL-1 cells were cultured to conﬂuency under an atmosphere of 95% air and 5% CO2 at 37°C,
trypsinised, counted and seeded in 500 µl of supplemented Claycomb medium in 8-well cham-
bered coverslides (Nunc Lab-Tek, SA). Approximately 15, 000 cells were seeded per well one
day prior to transfection, to reach 50-80% conﬂuency at the time of transfection.
4Professors Gavin Welsh and Jeremy Tavaré from the University of Bristol, Bristol, UK, kindly donated the
GLUT4 construct. Dr Craig Kinnear (Department of Medical Biochemistry, Stellenbosch University, Tygerberg,
South Africa) assisted by amplifying the construct.
Stellenbosch University http://scholar.sun.ac.za
CHAPTER 2. MATERIALS AND METHODS 44
Figure 2.7: Simplistic diagrammatic scheme representing the HA-GLUT4-GFP model used to analyse
GLUT4 translocation. [A] GFP indicates the presence of GLUT4 in the cell. [B] Insulin stimulation
enhances GLUT4 translocation to the cell membrane. Once GLUT4 associates to the membrane, the
HA-tag is exposed to the extracellular environment allowing binding of HA-antibody. A ratio of cell
surface GLUT4 (HA) to total GLUT4 (GFP) can thus be calculated per cell.
24 hours after seeding, the cells were transfected [Figure 2.8] using the Lipofectamine LTX
and PLUS Reagents (15338-100 Invitrogen, Carlsbad, CA) according to the Standard Pro-
tocol [refer Transfection protocol, Appendix E.1]. In brief, the medium was replaced with 500
µl fresh supplemented medium [Appendix A.1] 24 hours after transfection, although it can be
refreshed within 4-6 hours of transfection. 45 hours after transfection, and 3 hours prior to
ﬁxing, the cells were serum starved for 3 hours. One hour into serum starving the cells were
treated with 10−6M dexamethasone for 2 hours. The cells were treated with 300 nM insulin 15
minutes prior to ﬁxing.
Cells were ﬁxed with 2% paraformaldehyde and probed overnight with a 1:50 dilution HA-
tagged primary antibody (2367S Cell Signalling Technology, Boston, MA) in PBS. After a
washing step, a 1:200 dilution of anti-mouse TxRed, secondary antibody (Invitrogen, Carlsbad,
CA) was added. Hoechst 33342 (B2261, Sigma-Aldrich, Steinheim, Germany) was used as
nuclear dye diluted 1:1000 in PBS (0.05 mg/ml). Cells washed three times with PBS and
mounted by using a drop of ﬂuorescent mounting medium (S3023, Dako North America Inc.,
Carpinteria, CA).
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Figure 2.8: Overview of the HA-GLUT4-GFP transfection treatment protocol. As a reference for non-
speciﬁc signal, a staining control was stained without primary antibody, but with secondary antibody
only. One group was left untreated to serve as control. The two remaining groups were stimulated with
insulin, and one of these were treated with dexamethasone. The preparation of DNA-lipid complexes
is described in greater detail in Appendix E.1. 1° ab; primary antibody. Dex; dexamethasone.
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2.4.2 Assessing HA-GLUT4-GFP transfection by
immunoﬂuorescence microscopy
An Olympus Cell^R system attached to an IX 81 inverted ﬂuorescence microscope (Olympus
Coorporation, Tokyo, Japan) was used to perform image acquisition. The microscope was
equipped with an F-view-II cooled CCD camera (Soft Imaging Systems, Olympus Biosystems
GmbH, Germany). Images were acquired using a Xenon-Arc burner (Olympus Biosystems
GmbH, Germany) as light source with 360 nm (for DAPI-based staining), 492 nm (for FITC-
based staining), and 572 nm excitation ﬁlters (for TxRed-based staining). A UBG triple-
bandpass emission ﬁlter cube (Chroma Technology Corp., Bellow Falls, VT) was used to collect
emission signal. For the z-stack image frame acquisition a step width of 0.4-0.5 µm, an Olympus
Plan Apo N 60 ×/1.42 or 100 ×/1.4 oil objective were utilised. The Cell^R imaging software
was used for image processing, background subtraction, projecting the images in a maximum
intensity format and data acquisition.
2.4.3 Assessing HA-GLUT4-GFP transfection by confocal
microscopy
Confocal microscopy was performed on an inverted Zeiss Axiovert 200M LSM 510 META micro-
scope (Carl Zeiss MicroImaging GmbH, Germany), a pulsed infrared laser (Mai Tai Deepsee
from Spectra Physics, Santa Clara, CA, USA) for 2-photon excitation and non-linear optical
(NLO) imaging. Argon laser lines were used to excite in the blue range at 458, 477, 488 and 514
nm, a solid state laser was used for excitation at 561 nm in the green range, and a HeNe laser
for the red range at 633 nm. The system is equipped with two conventional confocal detec-
tors, as well as a polychromatic, spectral detection channel (META-detector) which allows for
simultaneous detection and separation of up to 8 emission spectra, although only three emis-
sion spectra were generated. Additionally, the system has a confocal detector for transmitted
light, which allows for optical sectioning of samples whether translucent, unlabelled or in com-
bination with ﬂuorescence labelling. An X-Cite 120 unit with a Xenon lamp (Lumen Dynamics
Group, Ontario, Canada) was used for epiﬂuorescence viewing of the specimens. Zeiss LSM and
Zen 2009 software (Carl Zeiss MicroImaging GmbH, Germany) were used, which automated
z-stacking for optimal increments of single image frames.
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2.5 Statistical analysis
GraphPad Prism 5 (GraphPad Sofware, La Jolla, CA) was used for statistical analysis. Results
were expressed as mean ± standard error of the mean (SEM). Data were analysed by one-way
analysis of variance (ANOVA) and Bonferroni post-test. Data from ﬂow cytometry experiments
were normalised to control values. Values were considered signiﬁcant when probability (p)-
values were less than 0.05 (p<0.05).
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Results
3.1 Culturing HL-1 cells
Culturing the HL-1 cardiomyocyte cell line requires careful attention, and a great deal of prepa-
ration and optimisation of culturing conditions. Appendix A contains detailed protocols and
tips for the Growth and care of HL-1 cardiomyocytes. Everything from supplementation of the
medium for various purposes [Appendix A.1 - A.3], to Passaging [A.6], to delicately Freezing
[A.7] and Thawing cells [A.8] is included.
A few key observations were made whilst establishing the HL-1 cells. Firstly, the cells are
very sensitive to CO2 levels. For a while cells presented inexplicable stunted growth, or even
death. Once it was discovered that incorrect CO2 levels were being displayed by the incubator,
and these levels were corrected, cells ﬂourished and were growing normally within 24 hours.
The second observation made was that crystals start to precipitate out of the medium while
culturing cells [Figure 4.1]. It is therefore essential always to use fresh medium to avoid this
problem.
One of the unique properties of this cell-line is that the cells have the capacity to be passaged
and remain diﬀerentiated and contract in culture [110]. For cells to continue beating, they
need to be supplemented with viable medium on a daily basis. It is critical that medium be
supplemented with norepinephrine (to a ﬁnal concentration of 0.1 mM) at least every two weeks
[refer Appendix A.1, Supplemented Claycomb Medium].
For the ﬁrst couple of weeks after enduring the courier process (live, at ambient temperature)
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from North America to South Africa, the cells exhibited very slow growth and no contractile
activity, again emphasising their delicate nature.
Lastly, cells were usually passaged 1:3, twice a week. Once seeded, cells do not immediately
exhibit any contractile activity. They grow for about three or four days until almost fully con-
ﬂuent, before single cells dispersed throughout the culture start displaying signs of polarization.
At this point adjacent cells start to contract until there are clusters of `beating' cells around
days 4-5.
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3.2 Measuring ROS by ﬂow cytometry
To assess whether oxidative stress was increased by dexamethasone, overall ROS was measured
via ﬂow cytometry [refer Section 2.2.2]. Our results indicate no statistically signiﬁcant diﬀer-
ences between the groups, however, a trend of elevated ROS (11%) was observed in cells treated
with 10−8 M dexamethasone for 4 hours. The experiment was carried out once so no statistical
analysis could be performed. The advantage of ﬂow cytometry, however, is that it enables data
to be obtained from an entire population, and a minimum of 5, 000 events were recorded per
sample [refer Figure 3.1].
Figure 3.1: ROS response to dexamethasone treatments (10−4 M, 10−6 M and 10−8 M,)
after 2, [A]; 3, [B]; and 4 hours, [C], respectively. All treatment groups have been normalised
to the control, and are represented as a percentage of control values. These are matched
observations where n=1 with at least 5, 000 events recorded per sample. Signiﬁcance could
not be determined, but the greatest increase in ROS (11%) was observed after 4 hours
exposure to 10−8 M dexamethasone. Dex; dexamethasone.
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3.3 Measuring the degree of O-GlcNAcylation
3.3.1 Flow cytometry measurement of O-GlcNAc
After looking into the eﬀects of dexamethasone on ROS, the eﬀects of the synthetic gluco-
corticoid on HBP ﬂux were assessed. Flow cytometry was employed to measure the degree
of O-GlcNAcylation [Figure 3.2]. Our results indicate no statistically signiﬁcant diﬀerences,
however, a trend of increasing O-GlcNAcylation (26.4 ± 12.59%) was observed in the group
exposed to 10−6 M dexamethasone for 2 hours.
Figure 3.2: Flow cytometry measurement of O-GlcNAc of cells treated with 10−4 M,
10−6 M, and 10−8 M dexamethasone. Treatments lasted 2, [A]; 3, [B]; and 4 hours, [C],
respectively. Results were normalised to controls and represented as a percentage of control
values. Matched observations were used to compare data sets, i.e. we employed an n=3 for
the 2 and 4 hour groups respectively, whilst we used an n=2 for the 3 hour treatment group.
On average ∼ 10, 000 events were recorded per sample. There were no signiﬁcant diﬀerences.
The most noteworthy change was the 26.4 ± 12.59% increase of O-GlcNAcylation after a 2
hour exposure to dexamethasone at a concentration of 10−6 M [A]. Dex; dexamethasone.
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Representative scatterplots and intensity histograms of the control and aforementioned dexa-
methasone group are shown in Figure 3.3. Mean intensity was measured in the gate P2, which
is a daughter population of P1, ensuring that only cells (and not debris) are considered for the
mean intensity analysis. The intensity histogram indicates an increase in ﬂuorescence intensity
of P2 in the dexamethasone-treated group (PE-TxRed peak shifts to right).
Figure 3.3: Flow cytometry measurements of O-GlcNAc in dexamethasone-treated cells. The greatest
increase of O-GlcNAcylation in relation to the control [A and C] occured after a 2 hour exposure to
dexamethasone at a concentration of 10−6 M [B and D]. The scatterplots [A and B] provide information
about granularity of the cells in the side scatter channel (SSC, y-axis); and can roughly equate particle
size allowing for diﬀerentiation between intact cells and cullular debris in the forward scatter channel
(FSC, x-axis). Intensiﬁed ﬂuorescence is indicated by the shift to the right in the PE-TxRed peak of
the representative intensity histograms [C and D].
3.3.2 Western blotting measurement of O-GlcNAc
Next, we determined O-GlcNAcylation by Western blotting [refer Figure 3.4]. Dexamethasone-
treated cells exhibited a similar amount of O-GlcNAc to the control group (Western blotting).
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For this set of experiments we also included an antioxidant (OHCA). However, OHCA treatment
resulted in no signiﬁcant changes in the degree of O-GlcNAcylation. No statistically signiﬁcant
diﬀerences were observed between groups.
Figure 3.4: [A] Western blot of O-GlcNAc (bottom), and the corresponding β-actin for loading
control (top). [B] Scanned images of the blots were digitised and, per lane, values normalised to
β-actin. Results are presented in arbitrary units. No signiﬁcant diﬀerences were observed (n=5).
AU; arbitrary units. Dex; dexamethasone. OHCA; α-cyano 4-hydroxyl cinnamic acid.
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3.4 Determining the degree of GLUT4 translocation
Both ﬂuorescence microscopy as well as confocal microscopy were used to investigate GLUT4
translocation with HA-GLUT4-GFP transfected cells, based on the HA:GFP ratio [refer Chap-
ter 2.4.1].
3.4.1 Immunoﬂuorescence microscopy
Dexamethasone signiﬁcantly reduced the HA:GFP ratio of insulin-stimulated cells. In compar-
ison to the control group [Figure 3.5], the HA:GFP ratio was reduced by 20.23 ± 0.993% in
insulin-stimulated, dexamethasone-treated cells [Figure 3.7]. In relation to insulin-stimulated
cells [Figure 3.6], dexamethasone treatment reduced HA:GFP by 20.53 ± 1.202%. No statis-
tically signiﬁcant diﬀerence was observed between control and insulin-stimulated cells [Figure
3.8].
Figure 3.5: Maximum intensity projections of the GFP, [A] and [B]; HA, [C] and [D]; and overlay
of all colour channels, including the blue nuclear stain, Hoechst, [E] and [F], of control cells. Where
green and red signal overlap, it presents as yellow or orange in the overlay. Fluorescence microscopy
images of HA-GLUT4-GFP transfected cells captured with a 60× oil immersion objective.
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Figure 3.6: Maximum intensity projections of the of insulin-stimulated, HA-GLUT4-GFP cells. GFP
is displayed in [A] and [B]; HA is represented in the TxRed channel, [C] and [D]; and [E] and [F] provide
an overlay of all colour channels, including the blue nuclear stain, Hoechst. Yellow or orange display
in the overlay images, [C] and [F], when green and red signal overlaps. Images were captured with a
60× oil immersion objective. The HA:GFP ratio was calculated per cell and used to determine mean
values for each treatment group.
Figure 3.7: Images of HA-GLUT4-GFP transfected cells that were insulin-stimulated and treated
with dexamethasone were projected at maximum intensity. [A] and [B] show GFP signal; [C] and [D],
the HA represented in the TxRed channel; and [E] and [F] display an overlay of all colour channels,
including the nuclear stain, Hoechst, in blue. Green and red signal overlapping results in yellow or
orange in the overlay. A 60× oil immersion objective was used. Per cell calculations of the HA:GFP
ratio were made for the group, and the mean value used to compare to other groups.
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Figure 3.8: The HA:GFP ratio represents the measure of GLUT4 present at the sarcolemma. Dexa-
methasone treatment of insulin-stimulated cells signiﬁcantly decreased the HA:GFP ratio in with re-
spect to the control (20.23 ± 0.993%) and insulin-stimulated groups (20.53 ± 1.202%). (n=7) Dex;
dexamethasone.
3.4.2 Confocal microscopy
We also made use of confocal microscopy to assess GLUT4 translocation [Figures 3.9, 3.10 and
3.11]. However, due to very low signal in the TxRed channel, no analyses could be performed on
these images in order to calculate the ratio of HA (surface GLUT4) to GFP (cytosolic GLUT4).
The images acquired do show the speciﬁc GFP signal which conﬁrms that the HL-1 cells were
transfected with the HA-GLUT4-GFP construct.
Figure 3.12 displays 4 layers from a z-stack taken of a cell stimulated with insulin and treated
with dexamethasone and OHCA. Here too, the TxRed signal was too poor to use for analysis
and they have been omitted from the ﬁgure. As the z-stack moves deeper into the cell e.g. from
[A] to [D] to [G] to [J], the diameter increases and more of the nucleus becomes visible as the
widest part of its girth is approached.
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Figure 3.9: A control cell transfected with HA-GLUT4-GFP that was neither treated with dexa-
methasone, nor stimulated with insulin, captured on a confocal microscope. [A] The green represents
GFP; [B] with the blue indicating nuclear material; [C] and the red, the HA-tag. [D] Lastly, an overlay
of all colour channels including a transmission image (grey) is displayed. The red scalebars represent
20 µm.
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Figure 3.10: Image of a cell transfected with HA-GLUT4-GFP and stimulated with insulin. [A] The
green represents GFP, [B] the blue indicates nuclear material, [C] and the HA-tag is shown in red, but
shows nothing more than a few (intracellular) specks of red, where one would expect a pericytosolic
accumulation. [D] An overlay of all colour channels is displayed last, and includes an image of the
transmitted light in grey. The red scalebars represent 10 µm.
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Figure 3.11: An HA-GLUT4-GFP transfected cell treated with dexamethasone and insulin-stimulated
imaged on a confocal microscope. [A] GFP is represented in green; [B] nuclear material in blue; [C]
and the HA-tag in red. [D] Finally all the colours are presented in an overlay which includes the grey
transmission image. The red scalebars represent 10 µm.
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Figure 3.12: Z-stack of an HA-GLUT4-GFP transfected cell. The red scalebars represent 10 µm.
Images [A] - [D] display the green channel representing the GFP; [E] - [H] display signal of the nuclear
dye, Hoechst, in blue; [I] - [L] provide overlay images of all colour channels, including the transmitted
light, in grey. This particular cell was stimulated with insulin and treated with dexamethasone and
OHCA.
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Discussion
4.1 Introduction
The metabolic syndrome, and related metabolic perturbations are closely linked to cardiomyo-
pathy and CVD. Insulin resistance is characteristic of metabolic disorders such as diabetes and
obesity. Hyperglycaemia signiﬁcantly induces glucose-utilising pathways [refer Figure 1.6] set-
ting oﬀ many adverse eﬀects. Increased ﬂux through the HBP, particularly when chronically
activated, plays a causative role in insulin resistance, T2DM, and CVD. More recently, stress
has also been implicated as a causative agent for the onset of insulin resistance [15], [114]
With this in mind, a cell model was established to gain insight into the eﬀects of dexametha-
sone on cardiac (HL-1) cells. We hypothesised that dexamethasone increases oxidative stress,
as well as HBP ﬂux increasing O-GlcNAc protein modiﬁcation, resulting in decreased GLUT4
translocation to the sarcolemma, and thus contributing to the onset of insulin resistance.
The hypothesis was tested by:
1. measurement of ROS in response to dexamethasone treatment, via ﬂow cytometry;
2. ﬂow cytometric measurement of O-GlcNAc in dexamethasone-treated cells;
3. analysis of O-GlcNAcylation following dexamethasone administration ± OHCA via West-
ern blotting; and
4. determining the degree of GLUT4 translocation.
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Our main ﬁndings indicated (1) no signiﬁcant increases in ROS, (2-3) or in O-GlcNAc mod-
iﬁcation, however, a deﬁnite trend towards an increase in O-GlcNAcylation subsequent to
dexamethasone treatment (2 hours, 10−6 M) was observed (2), [Chapter 3.3.1]. Furthermore, a
signiﬁcant decrease of GLUT4 translocation was also observed (4), [Chapter 3.4.1].
4.2 HL-1 cells
Cell growth is aﬀected by CO2 levels since it dissolves easily into water - or in this case the
culture medium - and aﬀects the pH. When CO2 dissolves into water it produces carbonic acid
(H2CO3), which quickly dissociates into bicarbonate (HCO3
−) and hydrogen (H+) ions [refer
Equation 4.2.1]. Increasing atmospheric CO2 will therefore decrease the pH. Similarly, cells
produce CO2 as they metabolise, which also increases the acidity of the medium. A phenol
red indicator (present in Claycomb medium) turns orange when medium becomes acidic, or
even yellow in cases of extreme acidity. To buﬀer this eﬀect, sodium bicarbonate (NaHCO3) is
frequently used in culture media to stabilize pH. NaHCO3 dissociates into sodium (Na
+) and
bicarbonate (HCO3
−) ions [refer Equation 4.2.2]. Dissolved CO2 is then in equilibrium with
bicarbonate ions.
CO2(g) +H2O(aq) −−⇀↽− H2CO3(aq) −−⇀↽− HCO−3(aq) +H+(aq) (4.2.1)
NaHCO3(aq) −−⇀↽− HCO−3(aq) +Na+(aq) (4.2.2)
When atmospheric CO2 is low, the pH of the medium will increase. We speculate that the
HL-1 cells exhibited retarded growth (discussed in Section 2.1.1) as a result of low atmospheric
CO2 levels (due to an incubator error) which resulted in excessive alkalinity in the medium,
indicated by a `cool', deep red appearance. Cells grow best at a relatively neutral pH, when
phenol red will give the medium a `warm' red appearance. CO2 levels may be maintained more
eﬀectively by minimising traﬃc through the incubator, and monitored with more regular, daily
measurements using a fyrite device.
We have also learnt that it is crucial that fresh medium is always used for the culturing of
HL-1 cells. If medium gets old, crystals may start to precipitate. Crystals assume what ap-
pears to be an octahedron shape, which is typical of sodium chloride (NaCl) crystals [Figure
4.1]. Regardless of their molecular make-up, once the crystal nucleus has formed the crystal
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continues to grow, and it has harsh edges that invade the space cells grow in, possibly obstruct-
ing cell growth.
Figure 4.1: Image of sodium chloride salt crystals similar in structure to those
which precipitate out of culture medium. Photograph by the NASA Expedition
6 crew (NASA Image of the Day). The crystals are in a water bubble within a
50 mm metal loop which formed part of an experiment in the Destiny laboratory
aboard the International Space Station.
Furthermore, medium should be supplemented with norepinephrine (to a ﬁnal concentration
of 0.1 mM) at least every two weeks [refer Appendix A.1, Supplemented Claycomb Medium].
Norepinephrine and retinoic acid are essential to stimulate beating, and maintain a diﬀeren-
tiated phenotype [110]. In summary, optimisation of HL-1 cell culturing conditions took a
considerable length of time and a signiﬁcant degree of time spent on this project.
4.3 Dexamethasone displays minimal eﬀect on ROS
Flow cytometry data for ROS measurement indicated little or no changes versus controls [refer
to Figure 3.1]. However, the 10−8 M dose of dexamethasone administered for 4 hours showed a
trend of elevated ROS levels compared to other doses.
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Oxidative stress has been shown to be involved in cell damage and myocardial cell death. It
has recently been found in rat cardiomyocytes that mitochondrial proteins (COX-1 of complex
IV of the electron transport chain, and NDUFA9 of complex I in particular) also undergo O-
GlcNAcylation, and especially when exposed to high glucose conditions [101]. This implicates
excessive mitochondrial O-GlcNAc modiﬁcation in adversely altered mitochondrial function.
Impaired mitochondrial function is well established in the diabetic cardiomyocyte [115]. Thus
a possible link may exist between O-GlcNAc-induced malfunctioning of the mitochondria and
superﬂuous superoxide release.
4.4 Eﬀect of dexamethasone on degree of
O-GlcNAcylation
4.4.1 Flow cytometry
There were no signiﬁcant increases in O-GlcNAcylation [Figure 3.2], as assessed by ﬂow cy-
tometry [Chapter 3.3.1], which corresponds to ROS data [Chapter 3.2]. The timepoint and
concentration that yielded the highest expression of O-GlcNAc was 2 hours with 10−6 M dexa-
methasone. We therefore used aforementioned treatment parameters for Western blotting, and
microscopy experiments (for GLUT4 translocation investigation) that followed.
4.4.2 Western blotting
When cells were treated with dexamethasone (10−6 M for 2 hours) and the antioxidant (OHCA)
was administered (250 µM for 90 minutes), and analysed by Western blotting for degree of O-
GlcNAcylation, no signiﬁcant diﬀerences were detected in any of the treatment groups [Figure
3.4]. This corresponds to our ROS data.
These data therefore suggest that dexamethasone did not activate the HBP in our experi-
mental system. It is important to note that O-GlcNAcylation is a very dynamic process that
cycles rapidly, and it is frequently in competition with phosphorylation for serine/threonine
sites. Therefore, with techniques such as ﬂow cytometry and Western blotting which use anti-
bodies that require ﬁxation of cells, only a `snapshot' in time can be assessed. Results gleaned
through such a small and warped window should thus be interpreted carefully. To improve sta-
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tistical accuracy it is recommended to increase the sample size, and perhaps use a more reliable
loading control. No literature was found regarding a direct link between glucocorticoids and
HBP activation.
4.5 GLUT4 translocation signiﬁcantly reduced by
dexamethasone
4.5.1 Immunoﬂuorescence microscopy
Dexamethasone treatment signiﬁcantly reduced HA:GFP ratio, which implies that GLUT4
translocation was decreased in this model [Figure 3.8]. Treatment with dexamethasone has
been associated with decreased glucose uptake in cells [35] and implies that dexamethasone
inhibits GLUT4 translocation or its association to the cell membrane [116]. It should be noted
that despite the decrease in translocation, GLUT4 protein content is often reported to in-
crease in rat (soleus) skeletal muscle [60], [117], while GLUT4 expression reportedly remains
unchanged in adipocytes [118]. In line with this, Vosseler et al. [97] deduced that insulin resis-
tance is induced by increased O-GlcNAcylation of GLUT4 rather than decreased expression of
the insulin-sensitive glucose transporter. However, further studies are required to conﬁrm these
hypotheses, and to elucidate the mechanisms of action. Although the complete mechanism
remains unclear, various sources of literature have veriﬁed the importance of PI3K and Akt in
insulin-stimulated GLUT4 traﬃcking [119]. Notably, dexamethasone has an attenuating eﬀect
on Akt expression [64], possibly explaining, at least in part, the reduction in insulin-stimulated
recruitment of the downstream target, GLUT4, to the sarcolemma.
An increase of the HA:GFP ratio is expected in the insulin-stimulated group. Shuralyova
et al. [28] (who conﬁrmed the presence of both isoforms of glucose transporters, GLUT1 and
GLUT4, in HL-1 cells) documented approximately a threefold increase in glucose uptake by
stimulating the cells with insulin (300 nM). No increase is, however, observed in our results.
This can possibly be explained by the fact that the culturing medium contains a small amount
of insulin (15 µg/l) [111] and that cells were never truly `serum starved' as a result. Conse-
quently, the cells weren't maximally sensitised to the insulin stimulation, and insulin could not
eﬀectively recruit GLUT4 vesicles to the sarcolemma. Thus our experimental system requires
further optimisation in terms of our conditions and to make meaningful conclusions. Further-
more, it appears that the TxRed signal (supposed to represent the presence of HA, and thus
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surface GLUT4) is relatively non-speciﬁc in most of the microscopy images.
4.5.2 Confocal microscopy
The TxRed channel in all the confocal microscopy images also contain what appears to be non-
speciﬁc signal. A cell from the control group is shown in Figure 3.9, while Figure 3.10 shows
a cell from the insulin-stimulated treatment group. Figure 3.11 displays a cell from the group
stimulated with insulin, and also treated with dexamethasone. In images from the ﬂuorescence
microscope it is less visible than those from the confocal microscope (far superior resolution). It
is possible, especially with ﬂuorescence microscopy, that HA signal from diﬀerent layers of the
z-stack, or signal from the bright GFP, may have `bled' through (dimensionally and spectrally,
respectively) and inﬂuenced ﬂuorescence intensity of HA. This would aﬀect the HA:GFP ratio
(mean ﬂuorescence intensity of HA divided by mean intensity of GFP). The power of the con-
focal microscope also clariﬁed the presence of HA signal within the cell, when the HA antibody
is expected to bind to the cell membrane, extracellularly. Figure 3.10 also displays a staining
artefact which looks like red contours arranged concentrically around the nucleus. This may be
due to the ﬂuorescent mounting medium used, or more speciﬁcally, it spreading unevenly in an
open well, as opposed to being covered by a cover slip on a microscope slide.
Interestingly, Figure 3.9 shows a transfected cell with a perinucleur GFP storage pool, typical
to GLUT4 distribution in cells [113], nestled in the concave side of the bean-shaped nucleus.
Perhaps there is an association between GLUT4 vesicle formation and the endoplasmic reticu-
lum and golgi stacks generally also found in this locale [120].
As with O-GlcNAcylation analyses, GLUT4 translocation analysis requires cells to be ﬁxed
for the use of HA antibody. This again meant that only a snapshot of the spacio-temporally
dynamic process could be captured. Another limiting factor was the very low transfection eﬃ-
ciency, typical of cardiac cells and particularly pronounced in the HL-1 cell line, which meant
that very few cells could be analysed by microscopy.
4.6 Conclusion
In an attempt to elucidate some of the underlying mechanisms driving the onset of stress-
induced cardiomyopathy, we successfully established a cell model for investigating the eﬀects
of glucocorticoids on cardiac cells. Firstly, we established the HL-1 cardioymyocyte cell line in
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our laboratory [described at length in Cell culture: Growth and care of HL-1 cardiomyocytes,
Appendix A]. This was followed by various time and dose response analyses for dexamethasone
treatment.
We aimed to assess oxidative stress in response to dexamethasone treatment. Here we found
that dexamethasone had no noticeable eﬀect on the overall production of ROS, however, this
does not rule out the change in production of mitochondrial ROS. Our second aim was to assess
the degree of O-GlcNAcylation in response to dexamethasone treatment. Here we found no
signiﬁcant changes from the control, but that dexamethasone increased protein modiﬁcation by
O-GlcNAc with a maximal eﬀect after a 2 hour treatment with a 10−6 M dose. These prelim-
inary data potentially implicate the HBP as a downstream target of glucocorticoids. Further
studies are needed to conﬁrm this.
Lastly, insulin-stimulated GLUT4 translocation was signiﬁcantly decreased subsequent to dexa-
methasone treatment. Dexamethasone has been linked to changes in GLUT4 translocation in
various tissues. Decreases in insulin-stimulated translocation in various tissues including muscle
and fat have been reported in literature. However, since insulin stimulation did not increase
GLUT4 translocation, further optimisation of the experimental protocol is required to mean-
ingfully investigate this question.
In conclusion, our data suggests a potential novel link between dexamethasone exposure, HBP
activation and decreased GLUT4 translocation. Based on our ﬁndings we propose that detri-
mental eﬀects of chronic stress on the heart may be mediated by increased HBP ﬂux. Consid-
ering that insulin resistance and thus indirectly, related metabolic derangements and diseases
such as diabetes, has been associated with glucocorticoid excess and GLUT4 dysregulation,
these results provide new targets for potential therapeutic agents.
Elucidation of these mechanisms and a search for an eﬀective therapeutic agent that may pre-
vent excessive or protracted O-GlcNAc modiﬁcation, and the consequent adverse eﬀects that
contribute to cardiovascular complications, remain part of ongoing research in our laboratory.
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4.7 Future recommendations
The inﬂuence of dexamethasone on O-GlcNAc modiﬁcation is poorly documented, especially
in the context of cardiovascular or metabolic diseases, making further investigation imperative.
Since our ﬂow cytometry results were inconclusive but indicated an upward trend in the ex-
tent of O-GlcNAcylation in response to certain doses of dexamethasone, signiﬁcance may be
reached with an increase in n's. The diﬀerences observed in O-GlcNAc were very small, thus
ﬂow cytometry may not be suﬃciently sensitive for its detection. Other techniques, such as
ﬂuorescence or confocal microscopy and Western blotting can be used to supplement the data.
Assessing the presence of OGT and OGA, or the availability of UDP-GlcNAc, may also provide
information about the extent of O-GlcNAcylation under diﬀering conditions.
We also propose that additional experiments be performed to conﬁrm the degree to which
dexamethasone plays a role in the production of myocardial ROS. Moreover, a mitochondrial
marker, e.g. MitoSOX Red, can be employed to assess mitochondrial changes per se, since the
DCF dye may not have detected minor changes in this regard. Further studies may also include
investigating the eﬀects of various anti-oxidants on ROS production. Additionally, investigating
the HL-1 cell line-speciﬁc reliance on glycolysis versus glucose oxidation would be of interest
with regards to mitochondrial respiratory-related ROS production.
Regarding HA-GLUT4-GFP analysis, optimisation of staining is required. A method by which
entry of the HA antibody into the cells could be minimised, thereby preventing non-speciﬁc
signal, entails incubating the viable cells with primary antibody prior to ﬁxation. If the anti-
body contains any toxic preservatives such as sodium azide, it should be puriﬁed by extensive
dialysis [121]. Milder ﬁxative agents may also limit non-speciﬁc entry of antibodies into cells.
Furthermore, since Claycomb medium contains insulin, the experimental conditions require op-
timisation in terms of eﬀective insulin-stimulated GLUT4 traﬃcking. Lastly, a glucose uptake
assay spanning a series of time points could assist in deﬁning the optimal time point at which
to assess GLUT4 translocation in HL-1 cells.
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Appendix A
Cell Culture: Growth and care of HL-1
cardiomyocytes
This appendix is adapted from the `Growth and care of HL-cardiomyocytes' document by
the Claycomb Lab. Establishing the cell line within the Cardio-Metabolic Research Group is
discussed in Section 2.1.1.
A.1 Supplemented Claycomb Medium
 Claycomb Medium (51800C, Sigma-Aldrich, Steinheim, Germany), [Table A.1] is ex-
tremely light sensitive so take care to wrap the containers (bottles and tubes) in foil.
 Make up small volumes of fresh supplemented Claycomb regularly - salt crystals start to
precipitate out of solution if the medium gets old.
 L-glutamine should be replenished after two weeks.
 Table A.2 shows what amounts of Claycomb medium, fetal bovine serum (ﬁlter-sterilised),
penicillin-streptomycin (optional), norepinephrine and L-glutamine are required to make
up 100 ml of supplemented Claycomb Medium.
A.1.1 Norepinephrine [(±) arterenol], MW 319.3 gmol−1
 Norepinephrine (10 mM stock) is made up in 30 mM ascorbic acid.
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Product Final concentration
Total protein 261 mg/l
Bovine albumin 48.85 mg/l
Nonessential amino acids 0.1 mM
Fetuin 165 mg/l
Transferrin 31.8 mg/l
Retinoic acid 300 µg/l
Human insulin (recombinant) 15 µg/l
Long R3IGF-1 (recombinant) 0.1 µg/l
Long EGF-1 (recombinant) 0.1 µg/l
Cholestrol 1.96 mg/l
Linoleic acid 0.78 mg/l
γ-Oleyl-β-pal-α-phosphatidylcholine 1.96 mg/l
Table A.1: Formulation of Claycomb Medium [111]
Product Volume Final concentration
Claycomb medium 87 ml
Fetal bovine serum 10 ml 10%
Penicillin/Streptomycin 1 ml 100 U/ml:100 µg/ml
Norepinephrine (10 mM stock) 1 ml 0.1 mM
made up in Ascorbic acid 0.3 mM
L-Glutamine (200 mM stock) 1 ml 2 mM
Table A.2: Supplemented Claycomb medium
 Add 0.59 g ascorbic acid (Sigma-Aldrich, Steinheim, Germany) to 100 ml of cell culture
grade distilled water. This makes a 30 mM ascorbic acid solution.
 To 25 ml of the 30 mM ascorbic acid solution, add 80 mg of norepinephrine.
 Filter-sterilise using a 0.2 µm Acrodisc syringe ﬁlter (FLAS25AC2050, Lasec, South
Africa).
 Aliquot into sterile, screw-cap microtubes in 1 ml volumes and store at -20°C.
 From this 10 mM stock norepinephrine, 1 ml in 100 ml medium will yield a ﬁnal concen-
tration of 0.1 mM.
 Make up fresh on a monthly basis.
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A.1.2 L-Glutamine
 L-Glutamine comes as a 100× solution (200 mM).
 Aliquot into working volumes and store at -20°C.
A.2 Wash Medium
Claycomb medium to be used as wash medium during passaging [Appendix A.6] had the fol-
lowing products added:
 5% fetal bovine serum (12103C, Batch 8A0177, SAFC Biosciences, Lenaxa, KS)
 1% (or 100 U/ml:100 µg/ml) penicillin-streptomycin (P4333, Sigma-Aldrich)
A.3 Freezing Medium
The solution cells are frozen in [see Appendix A.7for Freezing cells ] contains dimethyl sulphoxide
(DMSO) which is a weakly acidic, polar aprotic solvent that serves a cryoprotectant function.
It prevents freezing damage that may result due to ice formation. Although DMSO is less toxic
than other members of its class, it is best not to expose cells to this solvent at room temperature
for prolonged periods of time. [See also Appendix A.8, Thawing cells ].
 Freezing medium is made up of 95% FBS/5% DMSO.
 This can be stored up to a week at 4°C.
A.4 Pre-coating ﬂasks: Gelatin/Fibronectin
A.4.1 Preparing Gelatin/Fibronectin
 Weigh 0.1 g gelatin (G9391, Sigma-Aldrich, Steinheim, Germany) into a 500 ml glass
bottle. Note that the gelatin tends to stick to any surface it makes contact with so try
getting it directly into the glass beaker/bottle without touching the sides. Avoid using
weighing boats or funnels.
 Add distilled water to the 500 ml mark, and autoclave. The gelatin will go into solution
while being autoclaved.
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 This makes a 0.02% gelatin solution.
 Dilute 1 ml ﬁbronectin (F-1141, Sigma-Aldrich, Steinheim, Germany) in 199 ml of the
0.02% gelatin solution and mix gently.
 Immediately aliquot 6-12 ml volumes into 15 ml conical (centrifuge) tubes.
 Freeze aliquots at -20°C.
A.4.2 Coating ﬂasks
 Before culturing cells, coat tissue culture ﬂasks with gelatin/ﬁbronectin (G/F) using 1-2
ml per T25 and 3-4 ml per T75 ﬂask.
 Cap the ﬂasks, and incubate for at least an hour at 37°C.
 Remove the gelatin/ﬁbronectin by aspiration adding cells to the ﬂasks.
A.5 Culturing cells
 Cultures are fed with supplemented Claycomb Medium [Appendix A.1] every weekday
(per T25; 3-5 ml daily)
 More medium can be added on Fridays to avoid feeding cells on weekends. 10 ml of
supplemented Claycomb Medium added to a T25 on a Friday afternoon does not need to
be changed until the following Monday morning.
 Passaging is the procedure for splitting cells. Depending on the growth rate, cells can
either be split 1:2 or 1:3, twice a week, for example, on Mondays and Fridays.
 It is recommended to maintain two sets of cells; a `working' set and one for freezing away
cells in order to keep backup stocks [see Passaging, Appendix A.6].
A.6 Passaging
After the cells are ﬁrst received, it is recommended that they be split when they reach conﬂuency.
Keep some cells as a `working' set, and to freeze away four ﬂasks into four cryovials for future
use [described in Section 2.1.1]. This can be achieved within a week of receiving the HL-1 cells.
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 It is recommended that cultures only be split once full conﬂuence is reached.
 Warm PBS, trypsin/EDTA, wash medium [Appendix A.2], and a small volume of sup-
plemented Claycomb medium [Appendix A.1] to 37°C.
 In the meantime, remove the gelatin/ﬁbronectin solution from the ﬂask(s), and add 2-4
ml supplemented Claycomb medium to each T25. Place in the incubator to warm medium
to 37°C.
 Rinse each T25 ﬂask (containing the HL-1 cardiomyocytes) brieﬂy with 2 ml (4 ml per
T75) of warm PBS.
 Pipette the PBS, and later the trypsin, onto the bottom of the ﬂask (side opposite the
cap) so as not to hit the cells directly.
 Rinse gently and remove by aspiration.
 Add 1 ml of 0.05% trypsin/EDTA per T25 ﬂask (3 ml per T75).
 Incubate for 1 minute at 37°C.
 Aspirate and add fresh 0.05% trypsin/EDTA (same volume).
 Incubate for an additional 2 minutes.
 Examine microscopically to see if cells are still adhered. If so, rap the ﬂask on the benchtop
to dislodge the remaining cells.
 Add and equal amount (1 ml per T25) of soybean trypsin inhibitor [Appendix A.6.1]
directly onto cells to inactivate the digesting enzyme.
 Transfer cells from the ﬂask into a 15 ml centrifuge tube.
 Use 5 ml wash medium to rinse the ﬂask and add to cells already in the 15 ml tube.
 Centrifuge at 500×g for 5 minutes.
 Meanwhile, retrieve the T25 ﬂasks with fresh, supplemented Claycomb Medium from the
incubator.
 Remove the tube containing the pelleted cells from the centrifuge and remove the super-
natant by aspiration.
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 Gently resuspend the pellet in 3 ml of supplemented Claycomb Medium.
 Transfer 1 ml of the cell suspension into each of the three labeled, gelatin/ﬁbronectin-
coated T25 ﬂasks.
 Each ﬂask now contains 5 ml of medium.
 If the cells are passaged on a Friday, use twice the volume of supplemented Claycomb
Medium per ﬂask.
A.6.1 Soybean Trypsin Inhibitor
Used to inactivate trypsin during passaging [Appendix A.6].
 In a beaker dissolve 25 mg of soybean trypsin inhibitor in 100 ml Dulbecco's phosphate-
buﬀered saline (PBS; Ca2+-free and Mg2+-free).
 Filter-sterilise into a 100 ml bottle using a 0.2 µm syringe ﬁlter.
 This is good for a month at -20°C.
A.7 Freezing cells
If new cells are received (or if stocks are low) it is recommended that 4 or more vials are frozen
as soon as possible after receipt of the cells [please see note under Passaging A.6, and Cell
stocks 2.1.1]. Freezing away stocks of cells allows you to return to earlier passages, and protects
you in case of contamination.
The content of one conﬂuent T75 ﬂask is usually frozen in one cryovial. When cells are needed
the cryovial is thawed [see Thawing cells A.8] into one T75 ﬂask. Alternatively, the contents of
one conﬂuent T75 ﬂask can be split 1:2 (into two vials), and each vial can be thawed into one
T25.
 Brieﬂy rinse the T75 ﬂask containing the HL-1 culture with 4 ml PBS warmed to 37°C.
 Remove PBS by aspiration.
 Add 3 ml of 0.05% trypsin/EDTA into the ﬂask and incubate for 1 minutes at 37°C.
 Remove the trypsin/EDTA and replace with 3 ml fresh 0.05% trypsin/EDTA.
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 Incubate for 2 minutes at 37°C.
 Examine under a microscope to check that cells are dislodged. If not, rap the ﬂask on the
benchtop to loosen adherent cells.
 Inactivate the trypsin enzyme with an equal amount (3 ml) of soybean trypsin inhibitor
[see Appendix A.6.1].
 Transfer the 6 ml into a 15 ml centrifuge tube.
 Rinse each empty ﬂask with 5 ml wash medium and transfer this to the 6 ml already in
the centrifuge tube.
 Centrifuge tube for 5 minutes at 500×g.
 Remove the wash medium by aspiration.
 Gently resuspend each pellet in 1.5 ml of freezing medium (95% FBS/5% DMSO) [Ap-
pendix A.3].
 Pipette resuspended cells into a cryovial.
 Place the cryovial containing the cells into a freezing jar (5100, Cryo 1°C Freezing Con-
tainer, Mr. Frosty, Nalgene Labware, Thermo Fisher Scientiﬁc, Rochester, NY) half-
ﬁlled with room temperature isopropropanol.
 Immediately place the freezing jar into a -80°C freezer. This will allow cells to freeze at
a rate of -1°C/minute. Six to twelve hours later, transfer the vial(s) to a liquid nitrogen
dewar.
A.8 Thawing cells
 Gelatin/ﬁbronectin (G/F)-coat [Appendix A.4] a tissue culture ﬂask in an incubator at
37°C.
 After at least an hour, aspirate the G/F from the culture ﬂask and replace with supple-
mented Claycomb Medium (5 ml per T25, 10 ml per T75).
 Place this ﬂask back into the incubator.
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 Transfer 10 ml of wash medium into an empty 15 ml centrifuge tube and warm in a water
bath to 37°C.
 Thaw cells quickly (about 2 minutes) by placing the cryovial in the water bath (37°C).
Work quickly to prevent damage to cells and reduce toxic eﬀects of DMSO [Appendix
A.3].
 Transfer to the 15 ml tube containing the wash medium and centrifuge for 5 minutes at
500×g.
 Remove the tube from the centrifuge and aspirate the supernatant.
 Resuspend the pellet gently in 5 ml (3 ml in a T25) supplemented Claycomb Medium and
add to the 10 ml medium already in the T75 ﬂask.
 Since the HL-1 cells need to be seeded at a high conﬂuency from the start to grow with
ease, and it was observed that cells may have a low viability after thawing, it may be
safer to start oﬀ in a T25.
 Replace the medium with 10-15 ml (4-8 ml per T25) fresh supplemented Claycomb
Medium 4 hours later, once the cells have attached.
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Staining protocol
Refer to Chapter [2.2].
B.1 Staining protocol prior to ﬂow cytometry and
microscopy
The staining protocol is very similar for a variety of procedures. See ﬂow cytometry [Section
2.2.1], immunoﬂuorescence microscopy [Section 2.4.2], as well as confocal microscopy [Section
2.4.3].Below is the basic protocol that can be adapted or optimised as needed. Remember to
work in the dark, and wrap samples (ﬂow cytometry tubes or microscopy slides) in foil, as the
ﬂuorochromes are light sensitive.
 Aspirate medium and rinse with ice cold, sterile PBS.
 Permeabilise cells with 200 µl ice cold methanol-acetone (1:1), or ﬁx cells with cold 2%
paraformaldehyde.
 Incubate on ice (4°C) for 10 minutes.
 Remove ﬁxative and leave to airdry for 10 minutes.
 In the meantime prepare 5% donkey serum in PBS (100 µl per well)
 Rinse cells with cold PBS three times.
 The ﬂow cytometry protocol would require centrifugation for washing steps [Appendix
C.1 contains an important note regarding this].
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 After washing add 100 µl of the 5% donkey serum and incubate for 20 minutes.
 Drain the serum but do not wash the cells.
 Incubate with 100 µl primary antibody dilution, e.g. 1:50 or 1:200 in PBS or donkey
serum (remembering that the staining control does not get any primary antibody) for at
least 90 minutes, or overnight for convenience.
 Remove the primary antibody and wash three times with PBS.
 Add 100 µl secondary antibody dilution (1:200 with PBS or donkey serum, but be consis-
tent). Brieﬂy centrifuge the secondary antibody dilution to remove any crystals. Incubate
for 30 minutes.
 Add 100 µl Hoechst (1:1000) or other nuclear dye, and incubate for 10 minutes.
 Wash three times
 Store wrapped in foil at -20°C for two weeks.
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Experimental protocol for analysis after
dexamethasone treatment
Refer to Chapter 2.2.
C.1 Flow Cytometry
Flow cytometry as technique is discussed in Chapter 2.2.1. Preparation of samples for ﬂow
cytometry, whether ﬁxing cells for O-GlcNAc staining [Section 2.2.3] or using a live stain such
as H2DCFDA for ROS [Section 2.2.2], requires multiple centrifugation and washing steps. With
every step the cells may be agitated and stressed, as well as cells and time being lost. To cut
down on the number of washing steps the cells were not centrifuged (to remove supernatant)
and washed and centrifuged again every time the protocol called for a washing step. Instead,
a large volume (2 ml) of PBS was added to the cells (in suspension with the smaller volume
(200 µl) of either the methanol-acetone ﬁxative, donkey serum, primary antibody, or secondary
antibody) before pelleting. This meant that whatever supernatant could not be aspirated and
was left on the pellet was greatly diluted. Cells were also spared the extra rounds of stressful
centrifugation.
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Appendix D
Western blotting
See Chapter 2.3.
D.1 Cell harvesting
 Cells are washed with ice cold PBS.
 Add PMSF to RIPA buﬀer to a ﬁnal concentration of 1 mM [Appendix D.1.1].
 Add ∼ 350-500 µl RIPA to each T25 ﬂask and leave for 10 minutes.
 Use a cell scraper to lift the adhering cells from the surface of the ﬂask.
 Transfer the cell lysates into microfuge tubes and either proceed with the protocol, or
store the lysates at -20°C for no longer than 2 weeks, or at -80°C for longer-term storage.
D.1.1 Modiﬁed RIPA buﬀer
100 ml of modiﬁed RIPA buﬀer contains:
 50 mM Tris-HCl: 790 mg of Tris (648310, Calbiochem, Merck, Darmstadt, Germany) and
900 mg of NaCl (582 23 20EM, Merck, South Africa) in 75 ml distilled water, adjusted
to a pH of 7.4;
 10 ml of 10% Nonidet P40 Substitute (74385, Fluka, Sigma-Aldrich, Steinheim, Germany);
 2.5 ml of 10% sodium deoxycholate (918250, BDH Laboratory Chemicals, Poole, Eng-
land);
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 1 ml of 100 mM ethylenediaminetetraacetic acid (EDTA, E9884, Sigma-Aldrich, Stein-
heim, Germany) pH 7.4;
 Phosphatase inhibitors
 500 µl 200 mM activated sodium orthovanadate (Na2VO3) (S6 508, Sigma-Aldrich,
Steinheim, Germany);
 500 µl 200 mM sodium ﬂuoride (NaF);
 Protease inhibitors
 500 µl of 200 mM phenylmethanesulfonyl ﬂuoride (PMSF) (P7626, Sigma-Aldrich,
Schnelldorf, Germany) to be added immediately before use;
 100 µl of leupeptin (L2884, Sigma-Aldrich, Schnelldorf, Germany) (from 1 mg/ml
water stock);
 80 µl soybean trypsin inhibitor (SBT1) (T9003, Sigma-Aldrich, Schnelldorf, Germany)
(from 5 mg/ml water stock);
 100 µl benzamidine (B6506, Sigma-Aldrich, Schnelldorf, Germany) (1 M stock); and
 1 ml Triton X-100.
Since products such as sodium deoxycholate are light sensitive, and protease inhibitors have
short half-lives it is preferable to work in a cold room, or keep buﬀer reagents on ice (except for
Triton X-100), and protect from light by covering container in foil. Make up to a ﬁnal volume
of 100 ml with distilled water and store at - 20°C. The ﬁnal concentrations of reagents in the
buﬀer should be as reﬂected in Table D.1.
D.2 Preparing lysates
 Cell lysates, if frozen, should be defrosted slowly, on ice and kept on ice where possible
for the remainder of the protocol.
 More PMSF can be added before cell lysates are sonicated using a Misonix S-4000 min-
isonicator (Misonix Inc, USA).
 Sonicate lysates at an amplitude of 10, three times 5 seconds per sample interspersed with
5 second intervals (ie. 5 seconds sonication, followed by 5 seconds rest, on ice if possible,
repeated twice more).
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Product Volume Final concentration
Tris 790 mg
NaCl 900 mg 50 mM
Distilled water 75 ml
10% Nonidet P40 Substitute 10 ml 1%
10% Sodium deoxycholate 2.5 ml 0.25%
EDTA (100 mM) pH 7.4 1 ml 1 mM
Triton X-100 1 ml
Phosphatase inhibitors
Na2VO3 (200 mM) 500 µl 1 mM
NaF (200 mM) 500 µl 1 mM
Protease inhibitors
PMSF (200 mM) 500 µl 1 mM
Leupeptin (1 mg/ml water) 100 µl 1 µg/ml
SBT1 (5 mg/ml water) 80 µl 4 µg/ml
Benzamidine (1 M) 100 µl 1 mM
Table D.1: Modiﬁed RIPA buﬀer to be made up to 100 ml and stored at -20°C.
 The samples may foam due to the detergents and reagents in the RIPA buﬀer. Allow this
to settle (about 1 hour).
 Centrifuge the lysates at 4000×g at 4°C for 10 minutes, and discard the pellets.
D.3 Protein quantiﬁcation: The Bradford method
Chapter 2.3.2 deals with the preparation of samples for Western blotting, starting with protein
determination. Firstly, a protein standard with which to compare other proteins is required.
This standard reference is prepared with varying, known concentrations of BSA. A 200 µg/ml
BSA solution is made using distilled water and is used to prepare the standard curve as shown
in Table D.2.
 As each of the prepared standards amounts to 100 µl, it is best for consistency's sake to
do the same with the lysates of unknown protein concentration. Use 5 µl of every cell
lysate sample, adding 95 µl of distilled water to each.
 Add 900 µl of Bradford reagent, [the working solution, Appendix D.3.1] to each of these
standards and unknown (cell lysate) samples.
 Vortex gently and allow to stand for ∼ 5 minutes.
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BSA (µl) BSA concentration (µg) Distilled water (µl)
0 0 (Blank) 100
10 2 90
20 4 80
40 8 60
60 12 40
80 16 20
100 20 0
Table D.2: Concentrations for standard curve.
 Read absorbances with a Cecil Aurius CE2021 spectrophotometer (Cecil Instruments Ltd,
UK) at 595 nm.
 If the absorbance reading for a cell lysate sample falls outside the range of the standards,
it should be diluted with RIPA buﬀer or water (although the detergents in the RIPA
buﬀer may interfere) and its absorbance measured again.
 Plot the standard curve; absorbancies of the BSA standards (on the y-axis) against their
concentration values (x-axis) in a linear fashion.
 The protein concentrations of the unknown samples can then be inferred from the standard
curve by obtaining the x-axis values corresponding to their absorbance readings.
D.3.1 Bradford Reagent
 Dissolve 500 mg Coomassie Brilliant Blue G in 250 ml of 95% ethanol.
 Add 500 ml phosphoric acid and stir.
 Make up to 1 litre with distilled water and mix thoroughly.
 Filter and store this stock solution at 4°C.
 Dilute the Bradford stock in a 1:5 ratio using distilled water, ﬁlter until it turns an almost
clear, light brown colour and use for protein quantiﬁcation.
D.4 Sample preparation for SDS-PAGE
Once protein concentrations of the lysates have been determined, samples need to be prepared
for denaturing SDS-PAGE [as mentioned in Section 2.3.2].
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 A sample buﬀer stock solution can be prepared by adding 150 µl mercaptoethanol to 850
µl sample buﬀer.
 The appropriate amount of protein (as calculated for each cell lysate sample in the pre-
vious step) should be added to a microfuge tube containing sample buﬀer equivalent to
half of the volume of the protein.
 The ratio of protein to sample buﬀer is thus 2:1.
 Following brief centrifugation in a Spectrafuge 24 D bench top centrifuge (Labnet Inter-
national Inc, USA), the samples can either be stored at -80°C for later use, or used for
Western blot analysis.
 Before proceeding with Western blotting, the samples should be boiled in boiling water
or heated on a heating block at 95-100°C for 5 minutes.
 Brief centrifugation will ensure that the sample collects at the base of the tube.
D.5 SDS-PAGE
 The following reagents are necessary for the preparation of polyacrylamide gels: 30%
acrylamide-bis, (Merck, Darmstadt, Germany); 1.5 M Tris - pH varies for stacking and
resolving gels; 10% SDS (L3771, Sigma-Aldrich, Steinheim, Germany); 10% ammonium
persulphate (112 37 50, Saarchem, Merck, South Africa); N,N,N'N'-tetramethilene di-
amine (TEMED) (10732, Merck, Darmstadt, Germany); and distilled water.
 In order to separate the proteins via SDS-PAGE, prepare the polyacrylamide gel [Table
D.3] in advance and cool to 4 °C.
10% Resolving gel 5% Stacking gel
Volume per (5 ml) gel (ml) Volume per (1 ml) gel (ml)
Distilled water 1.9 0.68
30% acrylamide 1.7 0.17
1.5 M Tris 1.3 (pH 8.8) 0.13 (pH 6.8)
10% SDS 0.05 0.01
10% ammonium persulphate 0.05 0.01
TEMED 0.002 0.001
Table D.3: Constituents of polyacrylamide gels for 10% resolving and 5% stacking gels, respectively
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 Remember to pour a layer (∼ 1 ml) of water or isobutanol on top of the resolving gel
while setting to prevent it from drying out. Rinse with water and remove as much excess
ﬂuid as possible before proceeding to cast the stacking gel.
 Work quickly when casting the gels and inserting the well comb as the gel starts to
polymerise as soon as the last ingredient has been added.
 Avoid bubbles as oxygen inhibits polymerisation of the gel. Note that incomplete poly-
merisation is a bigger problem with stacking gels than resolving gels. Take particular
care not to trap bubbles beneath the comb as the poor polymerisation will lead to badly
formed wells.
 The cast gel can be stored in the fridge overnight wrapped in moist paper towel and cling
wrap to prevent it from drying out.
 Best resolution is achieved when gels and buﬀers are kept cool.
 Assemble the cassette to hold gel(s), using a buﬀer dam if only one gel is present.
 Load samples into the wells of the gel, remembering to save at least one lane for ∼ 4 µl
of molecular weight marker.
 Once the assembled cassette had been ﬁlled with running buﬀer [Appendix D.5.1], the
electrophoresis can commence.
 SDS-PAGE is recommended at 80 V for an initial 10 minutes, and then 100 V for a further
80 - 120 minutes, or until the protein(s) of interest have separated satisfactorily [Section
2.3.4].
D.5.1 Running buﬀer
 10 g SDS
 30.3 g Tris
 144.1 g Glycine (G8898, Sigma-Aldrich, Steinheim, Germany)
 Make up in 800 ml of distilled water
 Adjust to 1 l
 Store at room temperature
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D.6 Electrotransfer
 Once proteins have been separated by electrophoresis they can be transferred from the
gel onto a PVDF membrane (0.45 µm Biotrace PVDF, 66543, PALL Corporation, Life
Sciences, Pensacola, FL) via electrotransfer [Section 2.3.5].
 Soak two pieces of blotting paper (1703969, Extra thick blot paper, Protean XL size,
Bio-Rad Laboratories, CA), a little larger than the size of the gel, in transfer buﬀer [see
D.6.1].
 Soak the membrane, roughly the same size as the gel, brieﬂy in methanol (∼ 15 seconds)
allowing a few seconds to airdry before soaking it in transfer buﬀer. Never touch the
membrane with bare hands - always wear gloves so as not to compromise integrity of the
membrane with residual ﬁngertip proteins or oils.
 The stacking gel can be cut oﬀ the rest of the gel and discarded. Lift the gel gently oﬀ
the glass plate to prevent tearing it.
 Onto the centre of the semi-dry transfer apparatus (Bio-Rad® Semi-Dry Transfer Cell,
Bio-Rad Laboratories, CA) place, in order from bottom to top; a piece of presoaked
blotting paper, the PVDF membrane, the gel, followed by the ﬁnal piece of blotting
paper.
 Be sure not to shift the gel on the membrane as this may cause 'smudges' of protein.
 Use a clean, moistened tube to roll over the stack and roll out any air bubbles.
 Transfer the proteins at 15 V, 0.5 A for 1 hour and 20 minutes.
 Once electrotransfer is complete, remove the blot and dry it on a clean surface. This will
help to ﬁx the proteins on the blot.
 Proceed, or block the membrane for an hour (1% BSA made up in TBS-T) to store it at
-20 °C.
D.6.1 Transfer buﬀer
Make up 1 litre of transfer buﬀer by mixing together the following items:
 100 ml 10× Tris/Glycine (TG) buﬀer (161-0771, Bio-RAD Laboratories, CA),
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 200 ml methanol (603-001-00-X, Merck, Darmstadt, Germany), and
 700 ml distilled water.
1× TG buﬀer contains 25mM Tris and 192 mM glycine (pH 8.3).
D.7 Probing the membrane
 After transfer the membrane can be washed in distilled water or Tris-buﬀered saline-Tween
(TBS-T) for 5 minutes.
 Washing is followed by blocking the non-speciﬁc binding sites on the membrane in 1%
BSA, made up in 50 ml TBS-T, for as long as the speciﬁc probing requires (from 40
minutes for O-GlcNAc to overnight for other proteins).
 Wash the membrane with TBS-T again for 5 minutes and repeat twice more.
 Incubate the membrane overnight with primary antibody at 4°C. Consider saving the
antibody for future blot procedures.
 The TBS-T washing step is repeated, i.e. 3× 5 minutes.
 Incubate the membrane with the appropriate secondary antibody for an hour at room
temperature, or overnight at 4°C.
D.7.1 TBS
For a 10× TBS:
 Dissolve 6.05 g Tris (50 mM) and 8.76 g NaCl (150 mM) in 800 ml of distilled water.
 Adjust the pH to 7.5 with 1 M HCl (∼ 9.5 ml).
 Adjust the volume to 1 l with distilled water.
 TBS is stable at 4°C for three months.
 Note that sodium azide inhibits peroxidase activity therefore it is not recommended as
an antimicrobial agent.
Stellenbosch University http://scholar.sun.ac.za
APPENDIX D. WESTERN BLOTTING 100
D.7.2 TBS-T
For a 1× TBS-T:
 Dilute the 10× TBS stock 1:9 with distilled water.
 Add 1 ml Tween 20 per liter of TBS for a ﬁnal concentration of 0.1%.
D.7.3 Detection of O-GlcNAc
 The membrane is washed after electrotransfer is completed and then blocked with 1%
BSA to prevent non-speciﬁc binding of antibodies.
 O-GlcNAc blots [Chapter 2.3.6] can be blocked between 40 to 60 minutes.
 Wash with TBS-T for 5 minutes, three times.
 Incubate the membrane overnight with a 1:1000 dilution of the O-GlcNAc primary anti-
body, CTD110.6 (Santa Cruz Biotechnology, CA), in TBS-T at 4°C.
 Wash with TBS-T again for 5 minutes, three times.
 Dilute the anti-mouse, HRP-conjugated secondary antibody at 1:4000 (1.25 µl in 5 ml
TBS-T) and add to the membrane for an hour at room temperature with gentle shaking.
 Wash thoroughly by repeating the TBS-T wash steps before developing the blot.
D.7.4 Detection of β-actin
 Before probing for β-actin the membrane needs to be washed after electrotransfer, and
then blocked with 1% BSA to prevent non-speciﬁc binding of antibodies.
 Block the membrane for 60 minutes.
 Wash with TBS-T for 5 minutes, three times.
 Incubate the membrane with a 1:1000 dilution of the the β-actin primary antibody in
TBS-T at 4°C overnight.
 Wash with TBS-T again for 5 minutes, three times.
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 Dilute the anti-rabbit, HRP-conjugated secondary antibody 1:4000 (1.25 µl in 5 ml TBS-
T) and add to the membrane for an hour at room temperature with gentle shaking.
 Wash thoroughly by repeating the TBS-T wash steps before developing the blot.
D.8 Developing the membrane
Refer to Chapter 2.3.7.
 Treat the membrane with a detection reagent such as ECL Western Blot Substrate (K820-
500, BioVision Incorporated, Mountain view, CA) for a minute (mixing the solutions in a
1:1 ratio, or as instructed). Ensure that the mixture covers the entire membrane evenly.
 Place the membrane between two transparancies in a hypercasette (12643, Amersham,
Buckinghamshire, UK), making sure not to trap any bubbles. The blot can then be
developed in a dark room.
 On top of this sandwiched membrane place a developing ﬁlm such as CL-XPosure Film
(34089, Thermo Scientiﬁc, Rockford, IL) and close the hypercasette to expose the ﬁlm.
 The length of exposure (the time the ﬁlm remains on, or exposed to the membrane) varies
between proteins and protocols, and depends on the strength of the fast-decaying signal
emitted by the light-sensitive detection reagent.
 β-actin blots develop well if exposed for a only a few seconds (∼ 5 seconds) whereas
O-GlcNAc blots may take a little longer (∼ 1 minute).
 Remove the ﬁlm and immerse it in developing solution for a while until you start to notice
bands developing on the ﬁlm (∼ 10 - 30 seconds).
 Rinse the ﬁlm brieﬂy in water before placing it in ﬁxative for ∼ 15 seconds.
 Densitometric analysis [refer Chapter 2.3.8] can then be performed on the blot.
D.9 Stripping membranes to reprobe
One membrane can be probed more than once, allowing for the same set of proteins (from the
same cells, treated and harvested under the same conditions) to be probed for more than one
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kind of protein. This not only means that the SDS-PAGE procedures can be avoided, but also
makes data acquired much more comparable.
 Wash the membrane in distilled water, three times for 5 minutes each.
 Immerse the membrane in 0.2 M sodium hydroxide (NaOH) (582 32 00EM, Merck, South
Africa) and shake gently on a belly dancer (The Belly Dancer, Stovall Life Science Incor-
porated, Greensboro, NC) for 5 minutes.
 Repeat the wash steps with distilled water.
 Block and probe again as desired.
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Appendix E
HA-GLUT4-GFP Transfection
E.1 Transfection Protocol
Refer to Chapter 2.4.1, and Figure 2.8.
Using the Lipofectamine LTX and PLUS Reagents (15338-100 Invitrogen, Carlsbad, CA)
DNA-lipid complexes can be prepared for each transfection sample by doing the following:
 Place 100 µl of unsupplemented medium in a microfuge tube - one for each well containing
cells. Note that the addition of antibiotics to transfection media may result in cell death.
 Add 800 ng plasmid DNA (HA-GLUT4-GFP construct) followed by thorough mixing.
 Add 0.3 µl PLUS  Reagent (about a third of the volume of Lipofectamine  LTX that
will be added).
 Mix gently and incubate at room temperature for 5 minutes.
 Mix Lipofectamine LTX before use, and add 0.9 µl (or 3× the amount of PLUS 
Reagent) directly to the diluted DNA. Mix thoroughly.
 Incubate for 30 minutes at room temperature. DNA-lipid complexes are stable for 6 hours
at room temperature.
Add ∼100 µl DNA-lipid complex dropwise to each well containing cells. Rock the plate gently
back and forth to mix. The total volume in each well now comes to 600 µl so be careful not to
spill. Incubate the cells at 37°C for 18 to 48 hours prior to testing for transgene expression.
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